

Exploring the Ring-Closing Metathesis for the Construction of the Solomonamide Macrocyclic Core: Identification of Bioactive Precursors

Iván Cheng-Sánchez, Paloma Carrillo, Antonio Sánchez-Ruiz, Beatriz Martínez-Poveda, Ana R. Quesada, Miguel Ángel Medina, Juan Manuel López-Romero, and Francisco Sarabia
J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.7b02988 • Publication Date (Web): 20 Apr 2018

Downloaded from <http://pubs.acs.org> on April 20, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Exploring the Ring-Closing Metathesis for the Construction of the Solomonamide Macrocyclic Core: Identification of Bioactive Precursors

Iván Cheng-Sánchez,^[a] Paloma Carrillo,^[b] Antonio Sánchez-Ruiz,^[c] Beatriz Martínez-Poveda,^[b] Ana R. Quesada,^[b] Miguel A. Medina,^[b] Juan M. López-Romero^[a] and Francisco Sarabia^{[a]*}


^[a] Department of Organic Chemistry; Faculty of Sciences. University of Malaga. Campus de Teatinos s/n. 29071. Malaga (SPAIN)

^[b] Department of Biochemistry and Molecular Biology; Faculty of Sciences. University of Malaga. Campus de Teatinos s/n. 29071. Malaga (SPAIN)

^[c] Organic Chemistry Section; Faculty of Pharmacy. University of Castilla-La Mancha. Avda Dr. José María Sánchez Ibáñez s/n. 02008. Albacete (SPAIN)

Telephone: 34-952 134258. Fax: 34-952 131941

Email: frsarabia@uma.es



1
2
3
4
5 **Abstract:** New synthetic strategies directed towards the novel cyclopeptides solomonamides
6
7 have been explored utilizing an olefin metathesis as the key reaction. In the various strategies
8
9 investigated, we worked on minimally oxidized systems and the olefin metathesis reaction
10
11 demonstrated efficiency and validity for the construction of the macrocyclic core. The described
12
13 synthetic strategies towards the solomonamides are well suited for the subsequent access to the
14
15 natural products and represent flexible and diversity-oriented routes that allow for the
16
17 generation of a variety of analogues via oxidative transformations. In addition, preliminary
18
19 biological evaluations of the generated solomonamide precursors revealed anti-tumor activity
20
21 against various tumor cell lines.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. INTRODUCTION

Recently isolated from the marine sponge *Theonella swinhoei*, the solomonamides A (**1**) and B (**2**) (Figure 1) are natural products with interesting and promising biological properties.¹ Structurally characterized by unprecedented cyclopeptidic-type frameworks, these natural products have become potential leads for drug discovery and join a broad and impressive family of other bioactive natural products provided by this marine sponge.² An exhaustive spectroscopic analysis of both compounds has resulted in the elucidation of their intricate cyclic structures, revealing the presence of three conventional amino acids (D-Ala, Gly and L-Ser) and an unprecedented 4-amino(2'-amino-4'-hydroxyphenyl)-3,5-dihydroxy-2-methyl-6-oxohexanoic acid (ADMOA) and its corresponding 5-deoxy derivative (AHMOA) for solomonamides A and B, respectively. Assignment of the absolute configurations of ADMOA and AHMOA required additional studies, involving a combination of spectroscopic and theoretical studies (QM *J* based analysis and DFT *J*/¹³C calculations), which resulted in the proposal of the depicted absolute configurations as the most likely. Biologically, solomonamide A (**1**) displayed potent anti-inflammatory activity, causing a significant 60% reduction of inflammation in an animal model of edema at 100 µg/Kg. Unfortunately, the extreme scarcity of the solomonamides has precluded a thorough biological evaluation. In fact, the anti-inflammatory activity of solomonamide B (**2**) was not evaluated due to limited amounts. The unique and unprecedented structures of the solomonamides, together with their intriguing biological properties, have generated intense synthetic activity.³ For example, the Reddy group⁴ has recently reported a total synthesis of a deoxy analogue of solomonamide B⁵ together with an array of simple unfunctionalized analogues,⁶ culminating with a total synthesis of the natural solomonamide B,⁷ which has led to a revision of the initially proposed structure as will be detailed later.





Figure 1. Originally Assigned Structures of the Solomonamides

Our ongoing interest in the discovery and development of new potential leads based on cyclopeptidic- and cyclodepsipeptidic-type compounds,⁸ prompted us to initiate a research program directed toward the total synthesis of this novel and unexplored class of cyclopeptides. With the aim of establishing a flexible and divergent synthetic strategy capable of providing not only the natural products, but also provide an entry into a plethora of analogues for biological studies, we sought to explore the ring-closing metathesis (RCM) reaction as the key step for construction of the macrocycle.⁹ This cyclisation step would be followed by an oxidation phase, which would incorporate the functional groups needed to reach the final oxidation stage found in the natural products. From a strategic perspective, we considered that the construction of the macrocyclic core at the 4,5-bond would be capable of providing rapid access not only to the final products, but also to analogues from late stage intermediates, allowing for the facile entry into numerous scaffolds. Furthermore, it is worthy to note that this synthetic strategy utilizes simple starting materials, avoiding the construction of the complex ADMOA residue, which can be constructed in the later stages of the synthesis through an epoxidation of the olefins **3-6**, followed by an oxirane-ring opening process to introduce the amine group. Accordingly, as detailed in Scheme 1, our delineated strategy in retrosynthetic terms begins with the straightforward amide disconnection of the L-serine residue, followed by the removal of the functional groups, which would be introduced by means of oxidative

1
2 manipulations (oxidation phase) of the resulting metathesis products. In this way, the synthetic
3
4 strategy would render the corresponding macrocyclic alkenes represented by the *cis*- $\Delta^{4,5}$
5
6 derivatives **3-6**, which would possess or not various functionalities at the benzylic position. All
7
8 these macrocyclic compounds, in turn, could be obtained from the corresponding acyclic
9
10 precursors **7-10** via a ring-closing metathesis process. Finally, the preparation of such
11
12 precursors would be achieved by simple peptidic-like assembly between the amine derivatives
13
14 of the corresponding Boc derivatives **11-12** and the olefinic acids **13** or **14** (Scheme 1, part A).
15
16 Preliminary results in this synthetic direction have been recently published¹⁰ and support the
17
18 viability of this approach. In this manuscript we wish to report a full account of all the synthetic
19
20 studies carried out in our laboratories which have been initiated upon the basis of the previous
21
22 retrosynthetic scheme. In addition, during the execution of this synthetic work, Reddy et al
23
24 published the total synthesis of solomonamide B, based on an elegant intramolecular Heck
25
26 reaction, which provided the advanced solomonamide precursor **15**. More importantly, the total
27
28 synthesis of solomonamide B led to the revision of the initially proposed structure for **2**, with
29
30 the correction of the configurations at C-3 and at C-4 positions to the (3*S*, 4*S*)-isomer
31
32 (compound **16**) instead of the proposed (3*R*, 4*R*) for solomonamide B (**2**) (Scheme 1, part B).⁷
33
34
35
36
37
38
39 As the present synthetic studies were initiated prior to the Reddy publication, we targeted the
40
41 initially proposed structures for the solomonamides.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Scheme 1. Retrosynthetic Analysis for the Solomonamides (A) and Synthetic Work by Reddy (B)

2. RESULTS AND DISCUSSION


2.1. Ring-Closing Metathesis at the C4-C5 Bond. Encouraged by the appealing features of this synthetic strategy, as mentioned above, we initiated the synthetic route. Our initial forays toward the solomonamide structures were conducted to demonstrate the viability of the olefin metathesis approach, based on the disconnection of the 4,5-positions bond, using the model compounds **24** and **25** (Scheme 2). To this end, the readily accessible dipeptides **24** and **25** were prepared from 2-bromo aniline **17** and the iodonitrobenzene derivative **18**,¹¹ respectively, according to the synthetic sequence depicted in Scheme 2, entailing a Stille reaction for compound **19**, and a sequential Stille reaction/reduction, for compound **20**. Couplings of the resulting anilines **19** and **20** with dipeptide **21**¹² furnished the corresponding dipeptides **11** and **22**, which, after Boc deprotection, were coupled with commercial acid **23** to yield the targeted ring-closing metathesis precursors **24** and **25**. Thus, **24** and **25** were treated with 10 mol% of Hoveyda-Grubbs 2nd generation (HG-II) catalyst in refluxing dichloromethane in the presence of *p*-benzoquinone¹³ to obtain the expected macrocycles **26** and **27** in excellent 75 and 79% yields, respectively, as the sole products of the reaction. The newly formed double bonds ($\Delta^{4,5}$) of **26** and **27** were determined in both cases to be exclusively in the *E*-configuration, as evidenced by a coupling constant *J* of 15.9 Hz, therefore revising our previous assignment, which was incorrect¹⁰ (Scheme 2).

Despite this stereochemical outcome, and with the possibility in mind that the structural pattern of the acyclic precursor could influence the double bond geometry and switch in favour to the desired *Z*-isomer,¹⁴ we continued with the assembly of compounds **11** and **14**¹⁰ in a manner similar to as described before for **24**, providing **8** in a 74% overall yield. Upon exposure of **8** to HG-II catalyst, the expected macrocycle **4** was not obtained, instead recovering starting material, together with a significant degree of decomposition. Attributing steric factors to this failed cyclisation, the silyl protecting group was removed by treatment of **8** with HF•pyr to give

allylic alcohol **7**. Various reports in the literature, describing metathesis reactions involving allylic alcohols, indicate that these structural systems may favour the closing process,¹⁵ although other studies point out that these systems result in detrimental effects for the metathesis reaction.¹⁶ Nonetheless, when allylic alcohol **7** was treated with the HG-II catalyst in dichloromethane at 40 °C in the presence of *p*-benzoquinone, the *E*-olefin **28** was obtained exclusively in a gratifying 71% yield, with no formation of the required *Z*-isomer **3**, as revealed by the ¹H NMR spectra of the crude reaction mixture (Scheme 3).



Scheme 2. Towards the Total Synthesis of Solomonamides: RCM of Model Compounds **24** and **25**




Scheme 3. Towards the Total Synthesis of Solomonamides: Synthesis of Macrocycle **28**

In parallel to these preliminary works, we accomplished related synthetic studies extended to more functionalised precursors that would provide for a shortened the path towards the completion of the synthesis of these natural substances. In this direction, we pursued the preparation of the macrocycles **5** and **6** (See scheme 1) as potential advanced precursors. In order to rapidly inspect the validity of this approach, we initially worked with a model system represented by the deoxy aromatic derivatives. Thus, the readily accessible allylic alcohol **29**¹⁷ was transformed into the aniline **30** by treatment with Zn/NH₄Cl. Following the delineated synthesis for previous compounds, **30** was coupled with dipeptide **21** to yield the coupled product **31** as a 1:1 mixture of diastereoisomers. The assembly of **31** with acid **23** was preceded by Boc deprotection under conventional acidic conditions, followed by amide coupling assisted by HATU. Disappointingly, the expected coupling product **32** was not detected, instead the derivative **33** was obtained as a result of a cationic rearrangement of the labile allylic alcohol **31**, which probably occurred during the Boc deprotection step under the acidic conditions used

(Scheme 4). Different attempts for removal the Boc group under mild acidic (TMSCl, TMSOTf, Sn(OTf)₂, TiCl₄, SnCl₄), neutral (I₂, TBAF, H₂O at reflux) or basic conditions (Na₂CO₃, K₃PO₄, NaO^tBu)¹⁸ resulted similarly unfruitful with the formation of rearranged byproducts, recovery of starting material or degradation, respectively. As a consequence of these results, we considered a direct coupling between aniline **30** and the peptidic fragment **36**, which was efficiently prepared by utilising solid phase peptide synthesis (SPPS) as described in Scheme 4. Thus, the coupling of aniline **30** and acid **36** provided the desired diolefinic precursor **32** in a 77% yield. Finally, the ring-closing metathesis of **32** under the same conditions as in previous cases, afforded the macrocyclic derivative **38** in a 73% yield as the *E*-isomer, supported by the *J*_{4,5} coupling constant (14.6 Hz), and as a 1:1 mixture of diastereoisomers (Scheme 4). Interestingly, the protected precursor **37**, prepared by silylation of **32** with TBSOTf, did not provide the corresponding macrocyclic derivative when it was treated with the HG-II catalyst under the same conditions used for **32**, indicating that steric factors may be responsible for the failed ring closure.


The extension of this synthetic scheme to the aromatic system contained in the natural products was initiated with the aldehyde **40** prepared from commercially available **39**.¹⁹ Subsequent treatment of aldehyde **40** with magnesium vinylbromide provided allylic alcohol **41**, which required the reduction of the nitro group to the corresponding amine to give **42**. This seemingly simple operation however proved more problematic than expected. For example, treatment of **41** with Zn/NH₄Cl did not provide the expected aniline **42**, instead a complex mixture of unidentifiable degradation products were obtained. We surmised that the benzyloxy group installed in the aromatic ring was playing a crucial role in the reactivity of the benzylic alcohol, making it especially sensitive even under the weak acidic conditions of the reduction reaction.



Scheme 4. Towards the Total Synthesis of the Solomonamides via Diolefin **32**

To circumvent this rather disappointing outcome, we decided to protect the hydroxyl group as the silyl ether **43**. However, the Zn-mediated reduction of the nitro group did not provide the expected aniline **44**, instead the result again was the formation of a complex mixture of degradation products. Other reduction methods, including LiAlH₄ or Ni-Raney, were attempted


but they also were unsuccessful. Finally, the more robust BOM (PhCH₂OCH₂-) protecting group proved to be the solution for this problematic reduction, as the BOM derivative **45** provided the expected aniline **46** when treated with Zn/NH₄Cl in a reasonable and reproducible 79% yield. The linkage of aniline **46** and dipeptide **36** was then performed as described above for **32** to obtain compound **47**, which was subjected to the ring-closing metathesis to provide macrocycle **48** in an excellent 84% yield as a 1:1 mixture of diastereoisomers and the *E*-olefin as the only detectable double bond isomer. It is intriguing that this ring-closing metathesis process proceeded in such good yield, despite the presence of a protecting group at the hydroxyl group of the diolefinic precursor (Scheme 5).



Scheme 5. Towards the Total Synthesis of the Solomonamides via Diolefin **47**

The implementation of this synthetic scheme onto the more functionalised system found in the natural products was then confronted by the assembly of acid **49**, prepared by SPPS (See Experimental Part) and **46** under conventional conditions employed in this work (HATU/DIPEA). However, no desired product **50** was obtained despite attempts with an array


1
2 of coupling reagents such as BOP, PyBOP, DIC/HOBt or DIC/HOAt. Reasoning that steric
3
4 hindrances around the acid **49** could explain this failure, we attempted the synthesis of the
5
6 advanced precursor **50** by sequential couplings of aniline **46** with the amino acid derivatives **34**
7
8 and **35** and the less sterically encumbered acid **14**. Unfortunately, the last coupling with acid
9
10 **14** did not provide the expected product **50**, instead a complex mixture of HATU derivatives
11
12 was obtained from the starting acid. Intrigued by these failed reactions, we turned our attention
13
14 to the simple aniline **30**, in which the hydroxyl group at C6 position was free, in order to
15
16 determine the reasons of the serious hurdles found during this synthetic course. To this end,
17
18 aniline **30** and acid **49** were coupled by treatment with HATU/DIPEA and the corresponding
19
20 coupling product **51** was obtained, albeit in a low 36% yield, with the unexpected cleavage of
21
22 the silyl protecting group. Several attempts of this reaction revealed its lack of reproducibility,
23
24 the silyl protecting group. Several attempts of this reaction revealed its lack of reproducibility,
25
26 confirming the difficulties of such a coupling. Although obtained in low yield, compound **51**
27
28 was in hand and we were in position to investigate the ring-closing metathesis reaction for this
29
30 more complex system. The reaction, undertaken under similar conditions as in previous cases,
31
32 did not give the expected macrocycle **52**, thus demonstrating the unsuitability of these substrates
33
34 in the construction of the macrocyclic core of the solomonamides via RCM. The reason for
35
36 failure is most likely due to the sensitivity of the reaction to steric factors arising from the
37
38 presence of substituents at both allylic and benzylic positions (scheme 6).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Scheme 6. Exploration of the RCM in More Complex Systems

In yet another attempt to access the macrocyclic solomonamide precursors functionalised at the benzylic position, we considered the incorporation of a ketone at this position, since this is the functional group present in the natural products. In addition, the generation of the α,β -unsaturated ketone system, after the macrocyclisation process, would allow for the rapid and facile access to an epoxide via oxidation of the double bond. Notably, we were skeptical about the success of the metathesis reaction in such a system, represented by compound **53**, given that the olefin is unactivated as it is conjugated (α,β -unsaturated phenylketone). Despite this concern, we opted to experimentally verify the chemical reactivity of **53** under the action of the Hoveyda-Grubbs and related catalysts.


To this aim, we prepared ketone **53** by oxidation of the alcohol **32** with MnO₂ and then, subjected to the catalytic action of the Hoveyda-Grubbs 2nd generation, keeping in mind the difficulty of this reaction due to the inactivated nature of the double bond of the α,β -unsaturated ketone system. Indeed, this reaction did not provide any desired product, even when the reaction was forced using drastic conditions (ex. toluene at 60 °C and 100 °C), instead providing recovered starting material in all cases. In another attempt to obtain cyclic ketone **54**, cyclic alcohol **38** was treated with MnO₂ but the result was similarly unsuccessful, with only starting material recovered and no detection of the coveted ketone **54** (Scheme 7).



Scheme 7. Exploration of the RCM of the Diolenic ketone **53**

Although a *Z*-geometry for the $\Delta^{4,5}$ double bond was proposed to provide access to the *syn*-1,2-difunctionalized system present at these positions in the natural products, the fact that we obtained instead the *E*-olefinic macrocycles in all cases represented an additional difficulty in this study to obtain the final targets. Nonetheless, this synthetic strategy was not discarded at this point, as synthetic methods are available to provide the required *syn* isomer from a *trans* double bond.²⁰ Consequently, we decided to continue with the present synthetic approach and the next step was to evaluate the feasibility of such compounds to provide more oxidized


1 derivatives through an oxidation phase that would give access to the final products. In this
2 sense, we studied the oxidation of compounds **27**, **28** and **48** as representative macrocyclic
3 precursors of the solomonamides. Thus, when **27** or **28** were subjected to the oxidative action
4 of *m*-CPBA, we found, to our dismay, that these reactions did not yield the expected epoxides
5 **55** or **56**. Instead, starting materials were recovered in both cases. In light of these discouraging
6 results, we attempted the epoxidation utilizing the dioxirane derived from
7 trifluoromethylketone,²¹ however the result was similarly frustrating, with no formation of any
8 desired oxidation products. Other oxidative reactions were screened, such as a dihydroxylation
9 reaction mediated by OsO₄, and electrophilic additions, mediated by the actions of bromine or
10 NBS, but these did not provide favorable results, not detecting formation of any of the possible
11 oxidation products. The poor solubility observed for these cyclic compounds in common
12 organic solvents could explain the lack of reactivity found for them towards the oxidative
13 reagents. However, the more soluble derivative **48** also proved to be unreactive when it was
14 subjected to the epoxidation reagents (*m*-CPBA and dioxirane species), resulting in the recovery
15 of starting material and no detection of epoxide **57** (Scheme 8). Theoretical studies are currently
16 in progress in order to justify the lack of reactivity exerted by these macrocyclic compounds.
17 Thus, initial results from DFT calculations carried out in solution showed that the HOMO
18 orbital of the molecules is centered around the intracyclic phenyl ring with a low electronic
19 density around the alkene moiety.²² This result suggests that the main reactive point for the
20 oxidant should not be the alkene, as it could be expected, but the aromatic ring. At this stage,
21 no further work was required to recognize that oxidation of the previous solomonamide
22 precursors was extremely hard to accomplish. Therefore, a new approach was considered.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



15 **Scheme 8.** Attempts of Oxidation of the RCM Products

16
17
18
19 **2.2. Ring-Closing Metathesis at the C5-C6 Bond.** Given the results obtained during the
20 synthetic studies towards the solomonamides utilizing the macrocyclic construction at the C4-
21 C5 bond, we turned our attention to the construction of the macrocyclic core of the
22 solomonamides at the C5-C6 bond. In relation to the synthetic strategy explored in the previous
23 section, the removal of the functional groups, which should be accessible during an oxidation
24 phase, would lead to the relatively simple precursor **58**. Whereas the styryl double bond could
25 be transformed into a ketone or an α -hydroxy ketone via Wacker or dihydroxylation oxidations
26 for solomonamides A and B, respectively, the introduction of the required amine group at the
27 C4 position was initially planned via a C-H activation. The syntheses of the key precursor **58**
28 would be performed by a RCM of the acyclic derivative **59**, whose synthesis would be achieved
29 by simple peptidic-like assemblies between the corresponding amine and olefinic acid. As in
30 the previous synthetic exploration, we preferred to initiate this study with the model compound
31 **63** to test the viability of the new synthetic proposal. The preparation of this RCM precursor
32 was successfully achieved from the simple aniline **60**²³ by sequential couplings with dipeptide
33 **21** and hydroxy acid **62**^{10,24} with HATU. With compound **63** in hand, we proceeded with the
34 olefin metathesis reaction by use of the HG-II catalyst in refluxing dichloromethane. However,
35 it was with much disappointment, that this reaction failed to afford any macrocyclic product,
36 leading instead to decomposition and/or polymerization, together with the recovery of some
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


starting material (~12%). Additional attempts that included more forcing conditions (toluene at 65°C or 100 °C) and other catalysts (Grubbs 1st and 2nd generations, Hoveyda-Grubbs 1st generation) were thwarted, with no detection of the desired macrocyclic product **64** (Scheme 9).



Scheme 9. Second Approach to the Solomonamides via RCM: The C5-C6 Disconnection

Despite these discouraging results, we decided to press forward with the synthetic strategy by exploring the ring closing metathesis in the real system represented by the product **59**. We reasoned that in the case of the metathesis precursor **59**, the electronic effect of the benzyloxy group at the *para* position with respect to the styryl double bond could exert a favourable effect in terms of reactivity for the unreactive olefin. In order to confirm this hypothesis, we prepared


1 the styryl derivative **67** from compound **65** in a very good overall yield. We then proceeded to
2
3 test the construction of the macrocyclic ring of the solomonamide model system **70**. To this
4
5 end, compound **67** was coupled with commercial acid **68** to obtain the acyclic precursor **69** in
6
7 a 74% yield. Having prepared compound **69**, we were primed to test our hypothesis regarding
8
9 the favourable electronic donating effect of the benzyloxy group on the ring-closing metathesis
10
11 reaction. Indeed, we were gratified to discover that cyclic compound **70** was obtained in a 43%
12
13 yield and, exclusively, as the *E*-isomer, when the acyclic precursor **69** was exposed to the HG-
14
15 II catalyst in refluxing dichloromethane in the presence of 1,4-benzoquinone (Scheme 10). In
16
17 light of this encouraging result, the ring-closing metathesis was extended to the advanced
18
19 intermediate **59**, which was efficiently prepared from the Boc derivative **67** and acid **62** in 86%
20
21 overall yield, according to the previously described fragment coupling protocol. To our dismay,
22
23 treatment of **59** with the HG-II catalyst, under the same conditions previously employed in
24
25 earlier cases, did not provide the coveted solomonamide precursor **58**, providing instead
26
27 degradation products and recovered starting material. A possible explanation for the failure of
28
29 the metathesis reaction is the formation of either the five-membered ring intermediate **A**,²⁵ by
30
31 chelation of the ruthenium carbenoid with the hydroxyl group, or the seven-membered ring
32
33 chelate intermediate **B**,²⁶ in which sequestration of the ruthenium carbenoid species occurred
34
35 through a hydrogen bond of the hydroxyl group with the chlorine atom, which could explain
36
37 the inactivation of the catalyst for the RCM (Scheme 10).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Scheme 10. RCM of the Acyclic Precursors **59** and **69**

As support for this mechanistic hypothesis,²⁷ we decided to protect the hydroxyl group to avoid the formation of the proposed unproductive intermediates. Therefore, the TBS derivative **71** was prepared in a good yield by treatment of **59** with TBSOTf in the presence of 2,6-lutidine.


The resulting silyl ether **71** was then subjected to the exposure of the HG-II catalyst and, to our delight, the macrocyclic product **72** was obtained in a reasonable 47% yield. The completion of the synthesis of the natural products should require an eventual removal of the TBS protecting group. With this future objective in mind, we proceeded with the desilylation reaction by treatment of **72** with HF•pyr. Surprisingly, the expected hydroxyl derivative **58** was not obtained, instead recovered starting material. Other fluoride-based reagents (TBAF, TBAF-AcOH) afforded the same frustrating result. Therefore, we decided to replace the TBS group with a more labile protecting group, choosing TES as a suitable alternative. Then, compound **73** was prepared by reaction of **59** with TESOTf/2,6-lutidine and its suitability as a viable substrate for the preparation of **58** was evaluated. Gratifyingly, the RCM reaction of **73** provided **74** in a similar yield as for **72** (53%) and its desilylation, by treatment with TBAF, yielded the desired macrocyclic **58** in 85% yield (Scheme 11).



Scheme 11. RCM of the Acyclic Precursors **71** and **73**: Synthesis of **58**

1
2 **2.3. Ring-Closing Metathesis at the C3-C4 Bond.** Prior to the completion of the synthetic
3
4 study towards the natural solomonamides, for which meaningful quantities of **58** or precursor
5
6 **74** were required, we opted to complete the exploration of the RCM reaction by exploring the
7
8 C6-C7 bond as another disconnection point to construct the macrocyclic system of the
9
10 solomonamides. This new disconnection strategy would be based on the retrosynthetic analysis
11
12 depicted in Scheme 12. Having established the viability of the RCM strategy for the
13
14 construction of the macrocyclic core of the solomonamides at two different sites, the C5-C6 and
15
16 the C4-C5 bonds, we decided to extend the RCM-based strategy to the C3-C4 position, scanning
17
18 all the options along the six-carbons chain contained in the ADMOA fragment. In this new
19
20 scenario, the removal of the functional groups at the C3 and C4 positions revealed the
21
22 compound **75** as a potential precursor for solomonamide B, which could be obtained from the
23
24 acyclic derivative **76** via RCM. In the synthetic direction, aldehyde **40** was transformed into the
25
26 amine **79** without problems according to the synthetic sequence described in Scheme 12. Our
27
28 experience gathered during the synthetic campaign led us to choose BOM as the most suitable
29
30 protecting group for the benzylic alcohol and to introduce sequentially the two amino acids (D-
31
32 Ala and Gly) through the Fmoc derivatives **34** and **35** to obtain compound **81**. Prior to the
33
34 preparation of the subtarget RCM precursor **76**, we considered the use of the commercially
35
36 available acid **82** to test the possibilities of this new strategy. Having prepared model compound
37
38 **83**, treatment with HG-II catalyst under similar reaction conditions as previously used, did not
39
40 provide the desired result with the no formation of the macrocyclic compound **84**. In fact, a
41
42 rational explanation for this result could be the formation of a stable 5-membered ring chelate
43
44 between the ruthenium carbene and the carbonyl group of the amide (intermediate **A**), which
45
46 renders the metallacyclobutane intermediate unreactive toward the retro [2 + 2] cycloaddition²⁸
47
48 (Scheme 12). At this stage, we decided to terminate this synthetic approach, taking into account
49
50 that this strategy could be reconsidered in the future by use of Lewis acids,²⁹ which could be
51
52
53
54
55
56
57
58
59
60

investigated as useful additives to promote the ring closure as has been demonstrated in cross-metathesis reactions bearing similar structural motifs.



Scheme 12. Third Approach to the Solomonamides via RCM: The C3-C4 Disconnection

2.4. Biological Activity of Solomonamide Precursors.

At this stage of the synthetic work, with an efficient route defined to obtain the final natural products, we were intrigued with the biological properties of the synthesized products, recognizing that the macrocyclic peptides represented unprecedented and novel molecular architectures of biological interest. For this reason, we decided to explore and investigate their biological activities. To this aim, we performed preliminary biological evaluations, which consisted of the measurement of the antitumor properties of selected compounds against a panel of various tumor cell lines. The chosen solomonamide derivatives for this study were **26**, **27**, **28**, **38**, **70**, **74** and **58** as representative compounds of the different scaffolds generated during the synthetic work. In addition, compound **85**, obtained from **27** by treatment with Na/NH₃ (See Figure 2), was included for this study to evaluate the effect of the protecting group upon biological activity.




Figure 2. Synthetic Solomonamide Precursors Submitted to Biological Evaluations

As a first attempt to characterize the biological activities of the synthetic solomonamide analogues, the cytotoxicity profile of the aforementioned compounds was examined using nine

1
2 different cancer cell lines (see Table 1), as well as a primary culture of non transformed bovine
3
4 aorta endothelial (BAEC) cells.³⁰ The results of these biological evaluations, summarized in
5
6 Table 1, clearly revealed a relevant cytotoxic activity for only one compound, **58**, which
7
8 displayed the best values of inhibition of the series in the low μM range, against all the tumor
9
10 cell lines. In addition, **58** was also cytotoxic against the endothelial cells line (BAEC), which
11
12 may indicate a putative antiangiogenic effect of this compound.³⁰ In contrast, the other
13
14 compounds were practically devoid of antitumor activity except compounds **28** and **70**, which
15
16 displayed cytotoxicity, particularly against the HL60 tumor cell line albeit moderately. From
17
18 these results, a highlight is the notable enhancement of activity observed upon introduction of
19
20 functional groups in the polyketide fragment contained in these compounds, as concluded when
21
22 biological activities of **70** and **58** are compared, or **27** and **28** for the case of the HL60 cell line.
23
24 In addition, the isomeric derivative of **58**, compound **28**, displayed similar antiproliferative
25
26 activity as **58** against HL60, but, in contrast, was inactive against the other cell lines, including
27
28 BAEC, revealing the importance of the position of the double bond of the molecule upon
29
30 biological activities. This structural effect is also reflected when the biological activities of the
31
32 isomeric compounds **27** and **70** are compared. In an attempt to make sense of this result,
33
34 molecular modelling studies were conducted for compounds **27**, **28**, **70** and **58** to obtain the
35
36 corresponding minimized structures (Figure 3).³¹ The resulting models revealed a certain
37
38 structural distorsion when **27** and **70**, on one side, and **28** and **58**, on the other, are compared,
39
40 respectively. Thus, whereas **70** and **58** are almost flat, **27** and **28** displayed considerable
41
42 twisting. These differences in the resulting minimized molecular structures may explain the
43
44 differences observed for the biological activities found for these compounds. Additionally, the
45
46 overall shape of **27** is very similar to **28**, and the same is evident also for **70** and **58**. In this case,
47
48 despite these conformational similarities, it is clear that the functional groups incorporated in
49
50 **28** and **58**, in particular the hydroxyl group, may exert a key biological interaction through a
51
52
53
54
55
56
57
58
59
60

hydrogen bonding interaction with an acceptor-type residue located at the active site of the biological targets. These interactions may justify the greater activities displayed by **28** and **58** compared with **27** and **70**, respectively.

Table 1. In vitro Antitumor Activities of Solomonamide Precursors against Various Tumor Cell Lines and BAEC (IC₅₀, μM)^a

Compound	HL60 ^b	KU812F ^c	U937 ^d	HT-1080 ^e	MDA-MB-231 ^f	U87MG ^g	HepG2 ^h	HT-29 ⁱ	U2OS ^j	BAEC ^k
26	> 50	> 50	> 50	> 100	> 100	> 100	> 100	> 100	> 100	> 100
27	> 50	n.d.	n.d.	> 100	> 100	> 100	> 100	> 100	> 100	43,8 ± 1,2
85	> 50	> 50	> 50	> 100	> 100	> 100	> 100	> 100	> 100	> 100
28	17,2 ± 6,6	n.d.	n.d.	> 50	> 50	n.d.	n.d.	n.d.	n.d.	> 100
38	> 50	> 50	> 50	> 100	> 100	> 100	> 100	> 100	> 100	> 100
70	20,5 ± 5,2	> 50	> 50	31,1 ± 2,8	> 100	> 100	> 100	> 100	> 100	69,6 ± 12,5
74	> 50	> 50	> 50	> 100	> 100	> 100	> 100	> 100	> 100	> 100
58	14,7 ± 4,4	14,0 ± 3,05	7,02 ± 2,32	16,3 ± 2,9	16,5 ± 1,01	34,8 ± 5,1	18,9 ± 1,5	13,3 ± 0,6	12,9 ± 3,1	18,1 ± 2,2

[a] In vitro cytotoxicities were determined according to the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye reduction assay as detailed in experimental part. The IC₅₀ values were obtained from semilogarithmic dose-response plots as the concentration of compound yielding a 50% of cell survival. [b] HL60: Human promyelocytic leukemia. [c] KU812F: Chronic Myelogenous leukemia. [d] U937: Histiocytic lymphoma. [e] HT1080: Human fibrosarcoma. [f] MDA-MB-231: Human breast adenocarcinoma. [g] U87MG: Glioblastoma. [h] HepG2: Hepatocellular carcinoma. [i] HT-29: Colorectal adenocarcinoma. [j] U2OS: Osteosarcoma. [k] BAEC: Non transformed bovine aortic endothelial cells.




Figure 3. Computer-generated Minimum-Energy Conformations for Compounds **27**, **28**, **58** and **70**

3. CONCLUSIONS

In conclusion, an extensive synthetic exploration directed towards the solomonamides was conducted based on a ring-closing metathesis as the key reaction for the rapid and efficient access to their macrocyclic cores. The result of this synthetic study was the establishment of an efficient ring closure process which proceeded in high yields and complete stereoselectivity. During the course of these efforts, unexpected hurdles arose along the way, mainly with: 1) the reactivity of the hydroxyl group at the benzylic position (compounds **31** and **41**); 2) the reactivity of diolefins containing allylic and homoallylic alcohols (compounds **7**, **8**, **32**, **47**, **59**, **63**, **71** and **73**) or containing a β,γ -unsaturated carbonyl system (case of compound **83**) toward the ruthenium catalysts, and 3) the reactivity of macrocyclic olefins (compounds **27**, **28** and **48**) toward oxidative reagents. Although many of these synthetic problems were overcome, others remained elusive and represent synthetic challenges for future works. In relation to the ring-closing metathesis reactions, many of the described findings support the observations and results reported by other authors for this reaction on this class of structural systems. More importantly, not only did we explore the scope and limitations of the ring-closing metathesis in the synthesis of the macrocyclic core of the solomonamides, but we also identified several structurally related solomonamide precursors possessing significant cytotoxicities against various tumor cell lines, including endothelial cells, in the low μM range. These preliminary biological evaluations of relatively simple compounds, devoid of the functional groups present in the natural counterparts, portend promising antitumor properties for the natural products and qualify them as new scaffolds of biological and medicinal interest. Therefore, the described chemistry highlights the benefits of the olefin metathesis reaction in the field of the total synthesis of natural products, featuring convergency and flexibility for structural diversity and has allowed the identification of

1
2 bioactive compounds with interesting antitumor properties. The completion of the
3
4 synthesis of the natural products, the design of new analogues based upon compound **58**,
5
6 and further biological studies to elucidate the mechanism of its antitumoral and
7
8 antiangiogenic activities are currently in progress and they will be reported in due course.
9
10

11 12 13 **EXPERIMENTAL SECTION**

14
15
16 **General Techniques.** All reactions were carried out under an argon atmosphere with dry,
17
18 freshly distilled solvents under anhydrous conditions, unless using aqueous reagents or
19
20 otherwise noted. All solvents used in reactions were dried and distilled using standard
21
22 procedures. Tetrahydrofuran (THF) was distilled from sodium benzophenone, and methylene
23
24 chloride (CH₂Cl₂) from calcium hydride. Yields refer to chromatographically and
25
26 spectroscopically (¹H NMR) homogeneous materials, unless otherwise stated. All solutions
27
28 used in workup procedures were saturated unless otherwise noted. All reagents were purchased
29
30 at highest commercial quality and used without further purification unless otherwise stated. All
31
32 reactions were monitored by thin-layer chromatography (TLC) using 0.25 mm silica gel plates
33
34 (60F-254) using UV light (254 nm) as visualizing agent and acidic ceric ammonium molybdate/
35
36 phosphomolybdic acid or potassium permanganate solutions and heat as developing agents.
37
38 Flash column chromatography (FCC) was performed using silica gel (60 Å, particle size 230-
39
40 400 mesh) under air pressure. All solvents used for chromatographic purifications were distilled
41
42 prior to use. ¹H and ¹³C NMR spectra were recorded on a Bruker DPX-400 MHz instrument
43
44 and calibrated using residual undeuterated solvent as an internal reference. Chemical shifts are
45
46 reported in ppm with the resonance resulting from incomplete deuteration of the solvent as the
47
48 internal standard (¹³CDCl₃: 7.26 ppm, s and 77.0 ppm, t; ¹³CD₃OD: 4.87 ppm, s, 3.31 ppm, quin
49
50 and 49.1 ppm, sep; ¹³C₂D₆OS: 2.49 ppm, quin and 39.52 ppm, sep). Data are reported as
51
52 follows: chemical shift δ/ppm (multiplicity, coupling constants *J* (Hz) and integration (¹H
53
54
55
56
57
58
59
60

1
2 only)). The following abbreviations were used to explain the multiplicities: s = singlet; d =
3
4 doublet; t = triplet; q = quartet; quin = quintet; b = broad; m = multiplet or combination thereof.
5
6 ¹³C signals are singles, unless otherwise stated. High resolution mass spectrometry (HRMS)
7
8 was performed on a H-ESI and APCI mass spectrometer in positive mode and using an ion trap
9
10 (Orbitrap) as the mass analyzer type. HRMS signals are reported to 4 decimal places and are
11
12 within ± 5 ppm of theoretical values. Specific optical rotations were recorded on a Perkin-Elmer
13
14 241 polarimeter with a sodium halogen lamp ($\lambda = 589$ nm) and a cell path length of 100 mm (*c*
15
16 given in g/100 mL). Melting points were collected using a Gallenkamp or a Griffin melting
17
18 point system using a gradient of 0.5 °C per min.
19
20
21

22
23 **Biological Material and Methods.** Bovine aortic endothelial cells (BAEC) were isolated by
24
25 collagenase digestion, as previously described,³⁰ and maintained in Dulbecco's modified
26
27 Eagle's medium (DMEM) containing glucose (1 g/L) supplemented with 10% FBS
28
29 (DMEM/10% FBS). All the cancer cell lines used in this study were obtained from the
30
31 American Type Culture Collection (ATCC). Human fibrosarcoma HT-1080, hepatocellular
32
33 carcinoma HepG2 and glioblastoma U87MG cells were maintained in Eagle's Minimum
34
35 Essential Medium (EMEM) supplemented with 10% FBS. Human colon adenocarcinoma HT-
36
37 29 cells and human osteosarcoma U2OS cells were maintained in DMEM containing glucose
38
39 (4,5 g/L) supplemented with 10% FBS. Human breast cancer carcinoma MDA-MB-231,
40
41 chronic myelogenous leukemia KU812F and histiocytic lymphoma U937 cells were maintained
42
43 in RPMI1640 medium supplemented with 10% FBS. Acute promyelocytic leukemia HL-60
44
45 cells were maintained in RPMI1640 medium supplemented with 20% FBS. All culture medium
46
47 contained glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50 µg/mL) and amphotericin
48
49 (1.25 µg/mL) and all cell lines were grown at 37 °C and humidified 5% CO₂ atmosphere.
50
51
52
53
54
55
56
57
58
59
60

Aniline 19. To a solution of bromoaniline **17** (1.0 g, 5.81 mmol, 1.0 equiv) and Pd[PPh₃]₄ (336 mg, 0.29 mmol, 0.05 equiv) in DMF (15 mL) was added dropwise allyltri-*n*-butyltin (2.2 mL, 6.97 mmol, 1.2 equiv). The solution was then heated at 80 °C for 12 h. After this time, the mixture was diluted with diethyl ether and washed with water. The organic layer was separated and washed with water four times, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 5% EtOAc in hexanes) to obtain aniline **19** (596 mg, 77%) as a yellow oil: R_f = 0.60 (silica gel, 20% EtOAc in hexanes); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.13 – 7.05 (m, 2 H), 6.78 (td, *J* = 7.4, 1.1 Hz, 1 H), 6.72 – 6.69 (m, 1 H), 6.04 – 5.92 (m, 1 H), 5.18 – 5.09 (m, 2 H), 3.64 (bs, 2 H), 3.33 (d, *J* = 6.1 Hz, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 144.8, 136.0, 130.2, 127.6, 124.0, 118.9, 116.1, 115.9, 36.5; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₉H₁₂N 134.0970; found 134.0967.

Aniline 20. To a solution of iodonitrobenzene **18**¹¹ (6.0 g, 16.90 mmol, 1.0 equiv) and Pd[PPh₃]₄ (3.0 g, 3.40 mmol, 0.15 equiv) in DMF (30 mL) was added dropwise allyltri-*n*-butyltin (6.4 mL, 20.30 mmol, 1.2 equiv). The solution was then heated at 60 °C for 15 h. After this time, the mixture was diluted with Et₂O and water. The organic layer was separated and washed with water four times, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100% Hexanes) to obtain the corresponding allyl derivative (3.3 g, 73%) as a yellow oil: R_f = 0.56 (silica gel, 20% EtOAc in hexanes); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.54 (d, *J* = 2.7 Hz, 1 H), 7.46 – 7.33 (m, 5 H), 7.28 – 7.25 (m, 1 H), 7.16 (dd, *J* = 8.5, 2.7 Hz, 1 H), 5.96 (ddt, *J* = 16.6, 10.1, 6.4 Hz, 1 H), 5.11 (s, 2 H), 5.09 – 5.07 (m, 1 H), 5.05 – 5.03 (m, 1 H), 3.62 (dt, *J* = 6.4, 1.4 Hz, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 157.4, 135.8, 135.4, 132.8, 128.7, 128.3, 127.5, 127.1, 120.4, 116.7, 110.3, 70.6, 36.3; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd

1
2 for C₁₆H₁₆NO₃ 270.1130; found 270.1129. To a solution of the allyl derivative obtained above
3
4 (1.5 g, 5.60 mmol, 1.0 equiv) in acetic acid (15 mL) was added Zn dust (1.0 g, 16.20 mmol, 3.0
5
6 equiv) in ten portions of 100 mg each over 30 min at 25 °C. The reaction mixture was stirred at
7
8 this temperature until completion monitoring by TLC (1 h) and then, quenched by addition of
9
10 10% NaOH solution at 0 °C. The mixture was extracted with CH₂Cl₂, and the organic phase
11
12 washed with water, dried over anhydrous MgSO₄, filtered and the solvent evaporated under
13
14 reduced pressure. The resulting residue was purified by flash column chromatography (silica
15
16 gel, 5% EtOAc in hexanes) to obtain **20** (773 mg, 65%) as an orange oil: R_f = 0.38 (silica gel,
17
18 20% EtOAc in hexanes); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.46 – 7.37 (m, 4 H), 7.35 – 7.30
19
20 (m, 1 H), 6.95 (d, *J* = 8.3 Hz, 1 H), 6.41 (dd, *J* = 8.2, 2.5 Hz, 1 H), 6.35 (d, *J* = 2.5 Hz, 1 H),
21
22 5.95 (ddt, *J* = 16.6, 10.5, 6.1 Hz, 1 H), 5.14 – 5.11 (m, 1 H), 5.11 – 5.08 (m, 1 H), 5.03 (s, 2 H),
23
24 3.67 (bs, 2 H), 3.26 (dt, *J* = 6.1, 1.5 Hz, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 158.6,
25
26 145.8, 137.3, 136.4, 130.9, 128.5, 127.8, 127.4, 116.9, 115.8, 104.9, 102.6, 69.9, 35.8; HRMS
27
28 (H-ESI) *m/z*: [M + H]⁺ calcd for C₁₆H₁₈NO 240.1388; found 240.1392.
29
30
31
32
33
34
35

36 **Dipeptide 22.** To a solution of aniline **19** (700 mg, 5.25 mmol, 1.0 equiv) and Boc-Gly-D-Ala-
37
38 OH (**21**)¹² (1.3 g, 5.25 mmol, 1.0 equiv) in DMF (15 mL) was added HATU (3.0 g, 7.88 mmol,
39
40 1.5 equiv) and DIPEA (1.0 mL, 5.25 mmol, 1.0 equiv) at 0 °C and the mixture was stirred for
41
42 12 h at 25 °C. After this time, a saturated aqueous NH₄Cl solution was added and the organic
43
44 layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic
45
46 layers were washed with brine, dried over anhydrous MgSO₄, filtered and the solvent
47
48 evaporated under reduced pressure. The crude product was purified by flash column
49
50 chromatography (silica gel, 20% EtOAc in hexanes → 50% EtOAc in hexanes) to obtain
51
52 dipeptide **22** (1.5 g, 81%) as a white foam: R_f = 0.60 (silica gel, 100% EtOAc); [α]_D²⁵ = – 6.23
53
54 (c 0.45, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.96 (bs, 1 H), 7.79 (d, *J* = 8.0 Hz, 1
55
56
57
58
59
60

1 H), 7.23 (dd, $J = 8.1, 1.7$ Hz, 1 H), 7.18 (dd, $J = 7.5, 1.5$ Hz, 1 H), 7.15 – 7.10 (m, 1 H), 6.87
2 (s, 1 H), 5.97 (ddt, $J = 16.2, 10.2, 6.0$ Hz, 1 H), 5.15 (dd, $J = 10.2, 1.6$ Hz, 1 H), 5.06 (dd, $J =$
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17.2, 1.6 Hz, 1 H), 4.64 – 4.55 (m, 1 H), 3.88 – 3.80 (m, 2 H), 3.41 – 3.33 (m, 2 H), 1.47 (d, $J = 7.0$ Hz, 3 H), 1.44 (s, 9 H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 170.4, 170.0, 156.2, 135.9, 135.4, 131.1, 130.2, 127.1, 125.8, 123.9, 116.5, 49.5, 38.7, 36.1, 31.3, 28.3, 17.8; HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{28}\text{N}_3\text{O}_4$ 362.2080; found 362.2079.

Dipeptide 11. To a solution of aniline **20** (730 mg, 3.10 mmol, 1.0 equiv) and Boc-Gly-D-Ala-OH (**21**) (752 mg, 3.10 mmol, 1.0 equiv) in CH_2Cl_2 (15 mL) was added HATU (1.7 g, 4.60 mmol, 1.5 equiv) and DIPEA (0.5 mL, 3.10 mmol, 1.0 equiv) and the mixture was stirred for 12 h at 25 °C. After this time, the reaction mixture was diluted with CH_2Cl_2 and washed sequentially with 1 N HCl and a saturated aqueous NaHCO_3 solution. The organic layer was separated, washed with brine, dried over anhydrous MgSO_4 , filtered and the solvent evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes) to obtain dipeptide **11** (1.15 g, 81%) as a pale brown solid: $R_f = 0.69$ (silica gel, 100% EtOAc); $[\alpha]_D^{25} = -3.41$ (c 0.10, CH_2Cl_2); mp = 83–84 °C; ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.07 (bs, 1 H), 7.62 (d, $J = 2.3$ Hz, 1 H), 7.44 – 7.27 (m, 6 H), 7.05 (d, $J = 8.5$ Hz, 1 H), 6.94 (d, $J = 7.3$ Hz, 1 H), 6.73 (dd, $J = 8.4, 2.6$ Hz, 1 H), 5.94 (ddt, $J = 16.2, 10.2, 5.9$ Hz, 1 H), 5.14 – 5.04 (m, 2 H), 5.02 (s, 2 H), 4.59 (p, $J = 7.0$ Hz, 1 H), 3.91 – 3.77 (m, 2 H), 3.37 – 3.23 (m, 2 H), 1.46 (d, $J = 7.0$ Hz, 3 H), 1.44 (s, 9 H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 170.1, 169.9, 157.9, 156.0, 136.9, 136.3, 130.8, 128.5, 127.9, 127.7, 127.5, 122.3, 116.2, 112.2, 109.4, 80.6, 70.0, 49.6, 39.2, 36.5, 28.2, 17.6; HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{34}\text{N}_3\text{O}_5$ 468.2498; found 468.2487.

Diolefin 24. TFA (5.0 mL) was added to a solution of dipeptide **22** (360 mg, 0.99 mmol, 1.0 equiv) in CH₂Cl₂ (60 mL) at 0 °C and the reaction mixture was stirred at 25 °C until depletion of starting material as judged by TLC (3 h). Then, the TFA excess was removed under reduced pressure to obtain the corresponding ammonium trifluoroacetate salt as a brown solid which was dissolved in DMF (10 mL). To this solution, Kosher acid **23** (0.1 mL, 0.99 mmol, 1.0 equiv), HATU (379 mg, 0.99 mmol, 1.0 equiv) and DIPEA (0.52 mL, 2.99 mmol, 3.0 equiv) were added and the resulting solution was stirred at 25 °C for 12 h. After this time, a saturated aqueous NH₄Cl solution was added and the organic layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The resulting residue was purified by flash column chromatography (silica gel, 30% EtOAc in hexanes) to obtain diolefin **24** (205 mg, 60% over two steps) as a white solid: $R_f = 0.23$ (silica gel, 100% EtOAc); $[\alpha]_D^{25} = -8.50$ (*c* 0.51, CH₂Cl₂); mp = 80-81 °C; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.82 (bs, 1 H), 7.29 – 7.27 (m, 1 H), 7.25 – 7.23 (m, 1 H), 7.21 – 7.17 (m, 1 H), 7.16 – 7.11 (m, 1 H), 6.64 (d, *J* = 6.4 Hz, 1 H), 6.17 (bs, 1 H), 5.98 (dt, *J* = 16.4, 6.3 Hz, 1 H), 5.83 (dt, *J* = 16.9, 5.8 Hz, 1 H), 5.19 – 5.14 (m, 1 H), 5.12 – 5.09 (m, 1 H), 5.08 – 5.01 (m, 2 H), 4.60 – 4.51 (m, 1 H), 3.98 (d, *J* = 5.4 Hz, 2 H), 3.41 – 3.35 (m, 2 H), 2.44 – 2.33 (m, 4 H), 1.48 (d, *J* = 7.0 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 173.1, 169.9, 169.1, 136.7, 136.0, 135.3, 130.4, 130.3, 127.4, 125.7, 123.6, 116.6, 115.9, 49.7, 43.1, 36.4, 35.4, 29.4, 17.9; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₁₉H₂₆N₃O₃ 344.1974; found 344.1965.

Diolefin 25. Dipeptide **11** (150 mg, 0.32 mmol, 1.0 equiv) in CH₂Cl₂ (20 mL) was treated with TFA (1.6 mL) in exactly the same manner as previously described for synthesis of **24**. A solution of the ammonium salt and Kosher acid **23** (30 μ L, 0.32 mmol, 1.0 equiv), in CH₂Cl₂ (10 mL) was treated with HATU (122 mg, 0.32 mmol, 1.0 equiv) and DIPEA (0.17 mL, 0.96

1
2 mmol, 3.0 equiv) and the resulting solution was stirred at 25 °C for 12 h. After this time, a
3
4 saturated aqueous NH₄Cl solution was added and the organic layer was separated. The aqueous
5
6 phase was extracted with EtOAc, and the combined organic layers were washed with brine,
7
8 dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The
9
10 resulting residue was purified by flash column chromatography (silica gel, 20% EtOAc in
11
12 hexanes → 80% EtOAc in hexanes) to obtain diolefin **25** (140 mg, 97% over two steps) as a
13
14 white solid: $R_f = 0.24$ (silica gel, 100%); $[\alpha]_D^{25} = -6.37$ (c 0.06, CH₂Cl₂); mp = 87-88 °C; ¹H
15
16 NMR (400 MHz, CDCl₃) δ (ppm) 8.02 (bs, 1 H), 7.63 (bs, 1 H), 7.45 – 7.28 (m, 6 H), 7.05 (d,
17
18 $J = 8.5$ Hz, 1 H), 6.74 (dd, $J = 8.4, 2.6$ Hz, 1 H), 6.43 (bs, 1 H), 5.94 (ddd, $J = 16.5, 11.1, 5.8$
19
20 Hz, 1 H), 5.81 (ddd, $J = 17.0, 11.2, 6.2$ Hz, 1 H), 5.15 – 5.04 (m, 4 H), 5.03 (s, 2 H), 4.60 – 4.52
21
22 (m, 1 H), 4.04 – 3.93 (m, 2 H), 3.37 – 3.24 (m, 2 H), 2.43 – 2.31 (m, 4 H), 1.46 (d, $J = 7.0$ Hz,
23
24 3 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 173.5, 170.8, 169.5, 157.7, 136.9, 136.7, 136.3,
25
26 136.0, 130.7, 128.5, 127.9, 127.5, 123.6, 116.1, 115.6, 112.2, 110.4, 70.0, 49.8, 43.1, 38.6, 36.2,
27
28 36.1, 29.3, 17.7; HRMS (H-ESI) m/z : $[M + H]^+$ calcd for C₂₆H₃₂N₃O₄ 450.2393; found
29
30 450.2390.
31
32
33
34
35
36
37
38

39 **Macrocycle 26.** Diolefin **24** (45 mg, 0.13 mmol, 1.0 equiv), Hoveyda-Grubbs 2nd generation
40
41 catalyst (8 mg, 0.01 mmol, 0.10 equiv) and *p*-benzoquinone (1 mg, 0.01 mmol, 0.10 equiv)
42
43 were dissolved in degassed CH₂Cl₂ (7 mL, 0.02 M) and the reaction mixture was heated at 40
44
45 °C for 12 h. After this time, the solvent was removed under reduced pressure and the resulting
46
47 crude product was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes
48
49 → 2% MeOH in CH₂Cl₂) to obtain macrocycle **26** (31 mg, 75%) as a white solid: $R_f = 0.56$
50
51 (silica gel, 10% MeOH in CH₂Cl₂); $[\alpha]_D^{25} = -6.11$ (c 0.08, MeOH); mp = 188-189 °C; ¹H NMR
52
53 (400 MHz, DMSO-*d*₆) δ (ppm) 8.50 (bs, 1 H), 8.45 (d, $J = 7.3$ Hz, 1 H), 8.37 (t, $J = 5.9$ Hz, 1
54
55 H), 7.46 (dd, $J = 7.8, 0.9$ Hz, 1 H), 7.23 – 7.09 (m, 3 H), 5.44 (dt, $J = 15.9, 5.4$ Hz, 1 H), 5.08
56
57
58
59
60

(dt, $J = 15.9, 6.4$ Hz, 1 H), 4.35 (p, $J = 7.1$ Hz, 1 H), 3.85 (dd, $J = 14.7, 6.4$ Hz, 1 H), 3.44 (dd, $J = 14.7, 5.7$ Hz, 1 H), 3.26 (dd, $J = 15.8, 3.6$ Hz, 1 H), 3.08 (dd, $J = 15.5, 5.1$ Hz, 1 H), 2.28 – 2.08 (m, 4 H), 1.31 (d, $J = 7.2$ Hz, 3 H); ^{13}C NMR (100 MHz, DMSO- d_6) δ (ppm) 173.1, 171.3, 170.8, 136.5, 134.4, 130.9, 130.3, 128.5, 127.1, 126.0, 125.9, 49.7, 43.7, 34.8, 31.1, 27.9, 17.1; HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{22}\text{N}_3\text{O}_3$ 316.1661; found 316.1655.

Macrocycle 27. Diolefin **25** (135 mg, 0.30 mmol, 1.0 equiv), Hoveyda-Grubbs 2nd generation catalyst (20 mg, 0.03 mmol, 0.10 equiv) and *p*-benzoquinone (4.0 mg, 0.03 mmol, 0.10 equiv) were dissolved in degassed CH_2Cl_2 (16 mL, 0.02 M) and the reaction mixture was heated at 40 °C for 12 h. After this time, the solvent was removed under reduced pressure and the resulting crude product was purified by flash column chromatography (silica gel, 30% EtOAc in hexanes \rightarrow 3% MeOH in CH_2Cl_2) to obtain macrocycle **27** (100 mg, 79%) as a white solid: $R_f = 0.5$ (silica gel, 10% MeOH in CH_2Cl_2); $[\alpha]_D^{25} = -4.97$ (c 0.07, MeOH); mp = 198–199 °C; ^1H NMR (400 MHz, DMSO- d_6) δ (ppm) 8.54 (bs, 1 H), 8.52 (d, $J = 7.3$ Hz, 1 H), 8.37 (t, $J = 6.0$ Hz, 1 H), 7.46 – 7.31 (m, 5 H), 7.29 (d, $J = 2.6$ Hz, 1 H), 7.06 (d, $J = 8.4$ Hz, 1 H), 6.77 (dd, $J = 8.4, 2.7$ Hz, 1 H), 5.41 (dt, $J = 15.9, 5.4$ Hz, 1 H), 5.13 – 5.05 (m, 1 H), 5.04 (s, 2 H), 4.36 (p, $J = 7.1$ Hz, 1 H), 3.86 (dd, $J = 14.8, 6.5$ Hz, 1 H), 3.43 (dd, $J = 14.7, 5.6$ Hz, 1 H), 3.20 (dd, $J = 16.4, 3.9$ Hz, 1 H), 3.03 (dd, $J = 16.2, 5.0$ Hz, 1 H), 2.28 – 2.03 (m, 4 H), 1.30 (d, $J = 7.2$ Hz, 3 H); ^{13}C NMR (100 MHz, DMSO- d_6) δ (ppm) 173.1, 171.2, 171.0, 157.4, 137.6, 137.3, 131.5, 130.7, 128.8, 128.2, 128.1, 128.1, 128.0, 125.8, 111.8, 69.7, 49.7, 43.4, 34.7, 33.7, 27.9, 16.8; HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{28}\text{N}_3\text{O}_4$ 422.2080; found 422.2074.

Diolefin 8. Dipeptide **11** (328 mg, 0.70 mmol, 1.0 equiv) in CH_2Cl_2 (20 mL) was treated with TFA (3.5 mL) in exactly the same manner as previously described for synthesis of **24**. A solution of the ammonium salt and acid **14**¹⁰ (171 mg, 0.70 mmol, 1.0 equiv), in CH_2Cl_2 (15

1 mL) was treated with HATU (400 mg, 1.05 mmol, 1.0 equiv) and DIPEA (0.35 mL, 2.10 mmol, 3.0 equiv) and the resulting solution was stirred at 25 °C for 12 h. After this time, a saturated aqueous NH₄Cl solution was added and the organic layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes) to obtain diolefin **8** (250 mg, 74% over two steps) as a white solid: $R_f = 0.73$ (silica gel, 100% EtOAc); $[\alpha]_D^{25} = -6.06$ (c 0.05, CH₂Cl₂); mp = 98-99 °C; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.12 (bs, 1 H), 7.68 (d, $J = 7.3$ Hz, 1 H), 7.54 (d, $J = 2.6$ Hz, 1 H), 7.44 – 7.27 (m, 5 H), 7.06 (m, 1 H), 6.78 – 6.71 (m, 1 H), 6.70 – 6.63 (m, 1 H), 5.92 (ddt, $J = 16.5, 10.2, 6.1$ Hz, 1 H), 5.79 (ddd, $J = 17.3, 10.3, 7.2$ Hz, 1 H), 5.27 (m, 1 H), 5.10 (m, 1 H), 5.01 (s, 2 H), 4.60 – 4.51 (m, 1 H), 4.33 (dd, $J = 17.1, 7.4$ Hz, 1 H), 4.15 – 4.04 (m, 2 H), 3.62 (dd, $J = 17.1, 4.6$ Hz, 1 H), 3.36 – 3.22 (m, 1 H), 2.32 (dq, $J = 13.7, 6.8$ Hz, 1 H), 1.42 (d, $J = 7.0$ Hz, 3 H), 1.10 (d, $J = 6.9$ Hz, 3 H), 0.94 (s, 9 H), 0.19 (s, 3 H), 0.17 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 175.5, 170.8, 169.8, 157.8, 138.2, 136.8, 136.3, 136.1, 130.9, 128.5, 127.9, 127.5, 122.7, 117.9, 116.3, 112.2, 109.9, 70.1, 49.8, 46.6, 43.1, 38.9, 38.5, 25.2, 18.1, 17.4, 16.2, 13.6, 2.9, -4.5, -4.7; HRMS (H-ESI) m/z : $[M + H]^+$ calcd for C₃₃H₄₈N₃O₅Si 594.3363; found 594.3365.

Diolefin 7. To a solution of diolefin **8** (90 mg, 0.15 mmol, 1.0 equiv) in THF (10 mL) was added HF•pyr (0.6 mL) at 0 °C and the mixture was stirred for 12 h. The reaction mixture was quenched with a saturated aqueous NaHCO₃ solution and diluted with EtOAc. The organic layer was separated and the aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 2% MeOH in CH₂Cl₂) to obtain diolefin **7** (60 mg, 83%) as a white solid: $R_f = 0.66$

(silica gel, 10% MeOH in CH₂Cl₂); $[\alpha]_D^{25} = -4.91$ (*c* 0.08, CH₂Cl₂); mp = 90-91 °C; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.16 (bs, 1 H), 7.69 (d, *J* = 7.1 Hz, 1 H), 7.56 (d, *J* = 2.6 Hz, 1 H), 7.43 – 7.28 (m, 5 H), 7.05 (d, *J* = 8.4 Hz, 1 H), 6.88 – 6.81 (m, 1 H), 6.73 (dd, *J* = 8.4, 2.6 Hz, 1 H), 5.93 (ddd, *J* = 16.3, 11.1, 6.0 Hz, 1 H), 5.80 (ddd, *J* = 17.3, 10.3, 7.2 Hz, 1 H), 5.28 (dd, *J* = 16.0, 2.2 Hz, 1 H), 5.20 (d, *J* = 10.3 Hz, 1 H); 5.14 – 5.04 (m, 2 H), 5.01 (s, 2 H), 4.59 – 4.48 (m, 1 H), 4.31 (dd, *J* = 17.2, 7.5 Hz, 1 H), 3.62 (dd, *J* = 17.1, 4.8 Hz, 1 H), 3.33 – 3.26 (m, 2 H), 2.35 (dq, *J* = 13.6, 6.8 Hz, 1 H), 1.41 (d, *J* = 7.1 Hz, 3 H), 1.09 (d, *J* = 6.8 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 175.5, 170.7, 169.9, 157.8, 138.4, 136.9, 136.3, 136.2, 130.8, 128.5, 127.9, 127.5, 122.8, 117.7, 116.3, 111.9, 109.9, 70.1, 49.8, 43.2, 36.4, 23.8, 19.6, 17.3, 13.5; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₂₇H₃₄N₃O₅ 480.2498; found 480.2502.

Macrocycle 28. Diolefin **7** (30 mg, 0.06 mmol, 1.0 equiv), Hoveyda-Grubbs 2nd generation catalyst (4.0 mg, 0.01 mmol, 0.10 equiv) and *p*-benzoquinone (1.0 mg, 0.01 mmol, 0.10 equiv) were dissolved in degassed CH₂Cl₂ (3 mL, 0.02 M) and the reaction mixture was heated at 40 °C for 12 h. After this time, the solvent was removed under reduced pressure and the resulting crude product was purified by flash column chromatography (silica gel, CH₂Cl₂ → 5% MeOH in CH₂Cl₂) to obtain **28** (20 mg, 71%) as a white solid: *R_f* = 0.44 (silica gel, 10% MeOH in CH₂Cl₂); $[\alpha]_D^{25} = -8.4$ (*c* 0.05, MeOH); mp = 203-204 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ (ppm) 8.67 (bs, 1 H), 8.49 (t, *J* = 5.5 Hz, 1 H), 7.46 – 7.29 (m, 6 H), 7.07 (d, *J* = 2.7 Hz, 1 H), 6.82 (dd, *J* = 8.3, 2.7 Hz, 1 H), 5.62 (dt, *J* = 15.9, 5.11 Hz, 1 H), 5.05 (s, 2 H), 4.98 (dd, *J* = 15.9, 7.0 Hz, 1 H), 4.32 – 4.23 (m, 1 H), 4.13 (dd, *J* = 6.6, 4.7 Hz, 1 H), 3.85 (dd, *J* = 14.3, 5.8 Hz, 1 H), 3.19 – 2.99 (m, 3 H), 2.68 – 2.64 (m, 1 H), 1.30 (d, *J* = 7.3 Hz, 3 H), 0.85 (d, *J* = 6.9 Hz, 3 H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ (ppm) 174.9, 171.5, 170.6, 157.5, 137.6, 137.5, 131.6, 131.0, 130.2, 128.8, 128.2, 128.1, 127.6, 113.3, 112.3, 72.7, 69.7, 49.6, 44.9, 43.6, 33.8, 16.9, 11.0; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₂₅H₃₀N₃O₅ 452.2186; found 452.2188.

Aniline 30. To a solution of allylic alcohol **29**¹⁷ (1.9 g, 10.60 mmol, 1.0 equiv) in EtOH (60 mL) was added a solution of NH₄Cl (2.8 g, 53.02 mmol, 5.0 equiv) in water (40 mL) followed by Zn dust (10 g, 159.06 mmol, 15.0 equiv) in ten portions of 1 g each over 30 min at 25 °C. The mixture was stirred at this temperature for 12 h and then the reaction mixture was diluted with CH₂Cl₂ and water, then filtered and rinsed with CH₂Cl₂. The filtrate was diluted with water and extracted with CH₂Cl₂, and the organic phase washed with brine, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The resulting residue was purified by flash column chromatography (silica gel, 10% EtOAc in hexanes) to obtain aniline **30** (1.4 g, 85%) as a yellow oil: *R_f* = 0.48 (silica gel, 40% EtOAc in hexanes); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.13 – 7.06 (m, 2 H), 6.75 (td, *J* = 7.5, 1.2 Hz, 1 H), 6.65 (dd, *J* = 7.9, 0.9 Hz, 1 H), 6.15 (ddd, *J* = 17.0, 10.4, 5.3 Hz, 1 H), 5.34 (dt, *J* = 17.2, 1.4 Hz, 1 H), 5.25 (dt, *J* = 10.4, 1.5 Hz, 1 H), 5.15 (d, *J* = 5.2 Hz, 1 H), 3.75 (bs, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 144.8, 138.3, 128.9, 128.0, 126.4, 118.6, 117.1, 115.4, 74.2; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₉H₁₂NO 150.0919; found 150.0907.

Dipeptide 31. To a solution of aniline **30** (1.3 g, 8.71 mmol, 1.0 equiv) and Boc-Gly-D-Ala-OH (**21**) (2.1 g, 8.71 mmol, 1.0 equiv) in CH₂Cl₂ (15 mL) was added HATU (3.6 g, 13.07 mmol, 1.5 equiv) and DIPEA (1.5 mL, 8.71 mmol, 1.0 equiv) and the mixture was stirred for 12 h at 25 °C. After this time, a saturated aqueous NH₄Cl solution was added and the organic layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes → 40% EtOAc in hexanes) to obtain dipeptide **31** (2.5 g, 76%, 1:1 mixture of diastereoisomers) as a white foam. Data assigned for the mixture of diastereoisomers: *R_f* = 0.56 (silica gel, 100% EtOAc); ¹H NMR (400 MHz, CDCl₃) δ (ppm)

1
2 9.75 (d, $J = 8.6$ Hz, 1 H), 7.96 (t, $J = 8.2$ Hz, 1 H), 7.39 – 7.28 (m, 1 H), 7.25 – 7.15 (m, 1 H),
3
4 7.10 (m, 1 H), 7.06 – 6.98 (m, 1 H), 6.08 – 5.92 (m, 1 H), 5.85 – 5.64 (m, 1 H), 5.20 (d, $J = 5.7$
5
6 Hz, 1 H), 5.16 – 5.07 (m, 1 H), 4.54 – 4.35 (m, 1 H), 3.89 – 3.62 (m, 2 H), 1.37 (s, 9 H), 1.33
7
8 (d, $J = 7.2$ Hz, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 170.5, 170.4, 170.4, 170.1, 170.1,
9
10 138.1, 138.1, 136.3, 128.6, 128.5, 128.1, 127.9, 124.4, 122.4, 122.3, 116.0, 115.9, 80.9, 60.4,
11
12 50.3, 50.1, 44.1, 44.0, 28.3, 28.3, 17.8, 17.8; HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for
13
14 $\text{C}_{19}\text{H}_{28}\text{N}_3\text{O}_5$ 378.2029; found 378.2034.
15
16
17
18
19

20 **Trifluoroacetate Derivative 33.** Dipeptide **31** (1.0 g, 2.65 mmol, 1.0 equiv) in CH_2Cl_2 (20 mL)
21
22 was treated with TFA (13 mL) in exactly the same manner as previously described for synthesis
23
24 of **24**. A solution of the ammonium salt and Kosher acid **23** (0.27 mL, 2.65 mmol, 1.0 equiv),
25
26 in CH_2Cl_2 (35 mL) was treated with HATU (1.0 g, 2.65 mmol, 1.0 equiv) and DIPEA (1.4 mL,
27
28 7.95 mmol, 3.0 equiv) and the resulting solution was stirred at 25 °C for 12 h. After this time, a
29
30 saturated aqueous NH_4Cl solution was added and the organic layer was separated. The aqueous
31
32 phase was extracted with EtOAc, and the combined organic layers were washed with brine,
33
34 dried over anhydrous MgSO_4 , filtered and the solvent evaporated under reduced pressure. The
35
36 resulting residue was purified by flash column chromatography (silica gel, 30% EtOAc in
37
38 hexanes) to obtain trifluoroacetate derivative **33** (784 mg, 65%) as a white solid: $R_f = 0.18$
39
40 (silica gel, 100% EtOAc); $[\alpha]_{\text{D}}^{25} = -9.14$ (c 0.12, CH_2Cl_2); mp = 109-110 °C; ^1H NMR (400
41
42 MHz, CDCl_3) δ (ppm) 8.62 (bs, 1 H), 7.55 – 7.35 (m, 2 H), 7.25 – 7.20 (m, 1 H), 7.18 – 7.12
43
44 (m, 1 H), 6.85 (d, $J = 15.4$ Hz, 1 H), 6.15 (dt, $J = 15.4, 6.6$ Hz, 1 H), 5.77 – 5.66 (m, 1 H), 5.01
45
46 – 4.90 (m, 4 H), 4.69 – 4.58 (m, 1 H), 4.01 – 3.90 (m, 2 H), 2.37 – 2.22 (m, 4 H), 1.42 (d, $J =$
47
48 5.4 Hz, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 173.8, 171.2, 169.9, 157.7, 136.7, 134.3,
49
50 132.0, 129.7, 129.1, 126.7, 126.3, 125.1, 123.1, 115.7, 113.1, 68.5, 49.8, 43.3, 35.1, 29.3, 17.4;
51
52 HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{25}\text{F}_3\text{N}_3\text{O}_5$ 456.1746; found 456.1752.
53
54
55
56
57
58
59
60

1
2
3
4 **Acid 36.** A 5 mL polypropylene syringe fitted with polyethylene porous disk charged with 2-
5 chlorotriyl chloride (CTC) resin (300 mg, L=1.3 mmol/g, 0.39 mmol, 1.0 equiv), was loaded
6
7
8
9 with a solution of Fmoc-D-Ala-OH (**34**) (364 mg, 1.17 mmol, 3.0 equiv) and DIPEA (0.23 mL,
10
11 1.36 mmol, 3.5 equiv) in dry DMF (3 mL). The resulting suspension was shaken at 280 rpm for
12
13 30 h, then the solution was unloaded and the resin was washed by shaking with dry DMF (5 x
14
15 3 mL). The resulting yellow resin was used in the next step.

16
17
18 The polypropylene syringe loaded with the yellow resin was treated with a solution of 20%
19
20 piperidine in DMF (3 x 3 mL x 10 min at 280 rpm). After the last run, the resin was washed
21
22 with dry DMF (5 x 3 mL) and loaded with a solution of Fmoc-Gly-OH (**35**) (232 mg, 0.78
23
24 mmol, 2.0 equiv), HOBt (105 mg, 0.78 mmol, 2.0 equiv) and DIC (0.15 mL, 0.97 mmol, 2.5
25
26 equiv) in dry DMF (3 mL). The resulting suspension was shaken at 280 rpm for 24 h, and then
27
28 the solution was unloaded and the resin washed with dry DMF (5 x 3 mL). The resulting yellow
29
30 resin was used in the next step.

31
32
33 To a 5 mL polypropylene syringe fitted with polyethylene porous disk and loaded with the
34
35 resulting Fmoc protected dipeptide was added a solution of 20% piperidine in DMF (3 x 3 mL
36
37 x 10 min at 280 rpm). After the last run, the resin was washed with dry DMF (5 x 3 mL) and
38
39 treated with a solution of Kosher acid **23** (80 μ L, 0.78 mmol, 2.0 equiv) HOBt (105 mg, 0.78
40
41 mmol, 2.0 equiv) and DIC (0.2 mL, 0.97 mmol, 2.5 equiv) in dry DMF (3 mL). The resulting
42
43 suspension was shaken at 280 rpm for 24 h, and then the solution was unloaded and the
44
45 resin washed with dry DMF (5 x 3 mL). The resulting yellow resin was treated with a solution
46
47 of CH₂Cl₂/AcOH/TFE (7:2:1, 3 mL) for 30 min. After that, the solution was collected and the
48
49 resin washed with CH₂Cl₂ (2 x 3 mL). All the collected organic solvents were evaporated under
50
51 reduced pressure and the resulting acid **36** (71 mg, 81 % overall yield from CTC resin) was
52
53 obtained as a white solid which not required further purification: $R_f = 0.21$ (silica gel, 100%
54
55
56
57
58
59
60

1
2 EtOAc); $[\alpha]_D^{25} = -5.21$ (c 0.07, CH_2Cl_2); mp = 89-90 °C; ^1H NMR (400 MHz, CDCl_3) δ (ppm)
3
4 6.91 (bs, 1 H), 6.62 (bs, 1 H), 5.84 (ddd, $J = 16.2, 11.1, 5.9$ Hz, 1 H), 5.10 (dd, $J = 17.1, 1.5$
5
6 Hz, 1 H), 5.04 (dd, $J = 10.3, 1.0$ Hz, 1 H), 4.63 – 4.53 (m, 1 H), 4.10 (dd, $J = 16.4, 5.5$ Hz, 1
7
8 H), 3.94 (dd, $J = 17.0, 4.9$ Hz, 1 H), 2.46 – 2.35 (m, 4 H), 1.48 (d, $J = 6.9$ Hz, 3 H); ^{13}C NMR
9
10 (100 MHz, CDCl_3) δ (ppm) 175.4, 175.3, 162.9, 136.7, 115.8, 42.5, 36.7, 31.6, 29.4, 23.3;
11
12 HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{10}\text{H}_{17}\text{N}_2\text{O}_4$ 229.1188; found 229.1194.
13
14
15
16
17

18 **Diolefin 32.** A solution of the aniline **30** (31 mg, 0.20 mmol, 1.0 equiv) and acid **36** (46 mg,
19
20 0.20 mmol, 1.0 equiv) in dry DMF (8 mL) was treated with HATU (76 mg, 0.20 mmol, 1.0
21
22 equiv) and DIPEA (40 μL , 0.20 mmol, 1.0 equiv) and the resulting solution was stirred at 25
23
24 °C for 12 h. After this time, a saturated aqueous NH_4Cl solution was added and the organic
25
26 layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic
27
28 layers were washed with brine, dried over anhydrous MgSO_4 , filtered and the solvent
29
30 evaporated under reduced pressure. The crude product was purified by flash column
31
32 chromatography (silica gel, 20% EtOAc in hexanes \rightarrow 80% EtOAc in hexanes) to obtain
33
34 diolefin **32** (55 mg, 77%, 1:1 mixture of diastereoisomers) as a white foam. Data assigned for
35
36 the mixture of diastereoisomers: $R_f = 0.37$ (silica gel, 100% EtOAc); ^1H NMR (400 MHz,
37
38 CDCl_3) δ (ppm) 9.83 (bs, 1 H), 9.66 (bs, 1 H), 8.16 (d, $J = 8.1$ Hz, 1 H), 8.11 (d, $J = 8.1$ Hz, 1
39
40 H), 7.32 – 7.23 (m, 4 H), 7.16 – 7.10 (m, 2 H), 7.06 (td, $J = 7.5, 0.7$ Hz, 2 H), 6.80 – 6.66 (m,
41
42 2 H), 6.14 – 5.99 (m, 2 H), 5.82 (dd, $J = 11.6, 5.2$ Hz, 1 H), 5.76 (dd, $J = 10.3, 6.2$ Hz, 1 H),
43
44 5.35 – 5.25 (m, 2 H), 5.24 – 5.22 (m, 2 H), 5.20 – 5.12 (m, 2 H), 5.07 (dd, $J = 18.3, 2.9$ Hz, 2
45
46 H), 5.04 – 4.99 (m, 2 H), 4.84 (bs, 2 H), 4.56 (dd, $J = 14.7, 7.4$ Hz, 1 H), 4.48 (dd, $J = 14.1, 6.9$
47
48 Hz, 1 H), 4.14 (dd, $J = 6.6, 2.7$ Hz, 1 H), 4.10 (dd, $J = 6.2, 3.2$ Hz, 1 H), 3.82 (d, $J = 4.8$ Hz, 1
49
50 H), 3.79 – 3.75 (m, 1 H), 2.40 – 2.29 (m, 8 H), 1.46 (d, $J = 7.8$ Hz, 3 H), 1.44 (d, $J = 7.8$ Hz,
51
52 3H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 174.0, 173.9, 170.5, 170.4, 169.4, 169.3, 138.4,
53
54
55
56
57
58
59
60

1
2 138.2, 136.8, 136.5, 131.0, 130.8, 128.5, 128.4, 128.4, 128.3, 128.1, 127.8, 124.3, 124.2, 122.2,
3
4 122.1, 115.8, 115.7, 115.7, 115.6, 50.6, 50.2, 42.9, 42.8, 35.3, 35.2, 31.9, 31.4, 29.6, 29.3, 17.7,
5
6 17.6; HRMS (H-ESI) m/z : $[M + H]^+$ calcd for $C_{19}H_{26}N_3O_4$ 360.1923; found 360.1917.
7
8
9

10
11 **Silyl Ether 37.** To a solution of **32** (45 mg, 0.14 mmol, 1.0 equiv) in CH_2Cl_2 (5 mL) was added
12
13 2,6-lutidine (30 μ L, 0.25 mmol, 2.0 equiv) at 0 °C and the mixture was stirred 10 min at this
14
15 temperature. After this time TBSOTf (60 μ L, 0.25 mmol, 2.0 equiv) was added at 0 °C and the
16
17 mixture was stirred 12 h at 25 °C. Then, the reaction was quenched by addition of H_2O . After
18
19 decantation of the organic layer, the aqueous phase was extracted with EtOAc, and the
20
21 combined organic layers were washed with brine, dried over anhydrous $MgSO_4$, filtered and
22
23 the solvent evaporated under reduced pressure. The crude product was purified by flash column
24
25 chromatography (silica gel, 20% EtOAc in hexanes \rightarrow 100% EtOAc) to obtain silyl ether **37**
26
27 (50 mg, 85%, 1:1 mixture of diastereoisomers) as a white solid. Data assigned for the mixture
28
29 of diastereoisomers: R_f = 0.80 (silica gel, 100% EtOAc); mp = 121-122 °C; 1H NMR (400 MHz,
30
31 $CDCl_3$) δ (ppm) 8.16 (dd, J = 8.1, 7.9 Hz, 1 H), 7.31 – 7.27 (m, 1 H), 7.12 – 7.03 (m, 2 H), 7.01
32
33 – 6.95 (m, 1 H), 6.42 (d, J = 5.2 Hz, 1 H), 6.03 – 5.91 (m, 1 H), 5.88 – 5.76 (m, 1 H), 5.33 –
34
35 5.10 (m, 3 H), 5.10 – 4.98 (m, 2 H), 4.47 (p, J = 6.9 Hz, 1 H), 4.02 – 3.96 (m, 2 H), 2.44 – 2.36
36
37 (m, 2 H), 2.37 – 2.31 (m, 2 H), 1.50 – 1.42 (m, 3 H), 0.91 (s, 9 H), 0.14 (s, 3 H), 0.00 (s, 3 H);
38
39 ^{13}C NMR (100 MHz, $CDCl_3$) δ (ppm) 172.7, 169.7, 169.7, 168.3, 168.2, 138.9, 138.7, 136.9,
40
41 136.4, 136.3, 130.5, 130.2, 128.7, 128.6, 127.9, 127.9, 124.4, 124.3, 122.3, 122.3, 115.7, 114.5,
42
43 114.4, 50.1, 49.9, 42.9, 38.6, 35.5, 29.4, 25.7, 19.1, 19.1, 18.3, 18.3, -4.9, -5.0, -5.1, -5.1; HRMS
44
45 (H-ESI) m/z : $[M + H]^+$ calcd for $C_{25}H_{40}N_3O_4Si$ 474.2788; found 474.2775.
46
47
48
49
50
51
52
53
54

55 **Macrocycle 38.** Diolefin **32** (30 mg, 0.08 mmol, 1.0 equiv), Hoveyda-Grubbs 2nd generation
56
57 catalyst (5.0 mg, 0.01 mmol, 0.10 equiv) and *p*-benzoquinone (1.0 mg, 0.01 mmol, 0.10 equiv)
58
59
60

1
2 were dissolved in degassed CH₂Cl₂ (4 mL, 0.02 M) and the reaction mixture was heated at 40
3
4 °C for 15 h. After this time, the solvent was removed under reduced pressure and the resulting
5
6 crude product was purified by flash column chromatography (silica gel, CH₂Cl₂ → 5% MeOH
7
8 in CH₂Cl₂) to obtain macrocycle **38** (21 mg, 73%, 1:1 mixture of diastereoisomers) as a white
9
10 solid. Data assigned for the mixture of diastereoisomers: R_f = 0.46 (silica gel, 10% MeOH in
11
12 CH₂Cl₂); mp = 153-154 °C; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.58 (dd, *J* = 14.1, 8.0 Hz, 2
13
14 H), 7.45 – 7.38 (m, 2 H), 7.30 – 7.20 (m, 4 H), 5.78 – 5.68 (m, 1 H), 5.58 – 5.51 (m, 1 H), 5.35
15
16 (dt, *J* = 14.6, 6.9 Hz, 1 H), 5.15 (d, *J* = 6.5 Hz, 1 H), 5.10 (d, *J* = 6.9 Hz, 1 H), 4.53 (q, *J* = 7.1
17
18 Hz, 1 H), 4.31 (q, *J* = 7.3 Hz, 1 H), 4.15 (d, *J* = 14.8 Hz, 1 H), 3.89 (d, *J* = 15.6 Hz, 1 H), 3.75
19
20 (d, *J* = 15.4 Hz, 1 H), 3.52 (d, *J* = 14.8 Hz, 1 H), 2.53 – 2.44 (m, 4 H), 2.41 – 2.26 (m, 4 H),
21
22 1.48 (d, *J* = 7.4 Hz, 3 H), 1.46 (d, *J* = 7.2 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 175.1,
23
24 174.9, 172.7, 171.7, 171.2, 171.2, 136.9, 136.7, 134.3, 133.9, 133.8, 133.5, 130.9, 129.9, 127.4,
25
26 127.3, 126.9, 126.4, 125.9, 125.8, 125.8, 125.3, 71.9, 71.6, 50.9, 49.6, 43.6, 42.7, 34.9, 33.5,
27
28 28.5, 26.8, 15.8, 15.5; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₁₇H₂₂N₃O₄ 332.1610; found
29
30 332.1588.
31
32
33
34
35
36
37
38

39 **Allylic Alcohol 41.** To a solution of nitrobenzaldehyde derivative **40**¹⁹ (1.8 g, 6.99 mmol, 1.0
40
41 equiv) in THF (25 mL) was added vinylmagnesium bromide (10 mL, 1.0 M in THF, 9.79 mmol,
42
43 1.4 equiv) at -78 °C. After being stirred for 3.5 h, the mixture was quenched with 25 mL of 0.01
44
45 N HCl, diluted and extracted with EtOAc three times. The combined organic layers were
46
47 washed with brine, dried over anhydrous MgSO₄, filtered and the solvent evaporated under
48
49 reduced pressure. The crude product was purified by flash column chromatography (silica gel,
50
51 5% EtOAc in hexanes) to obtain allylic alcohol **41** (1.8 g, 90%) as a yellow oil: R_f = 0.79 (silica
52
53 gel, 40% EtOAc in hexanes); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.66 (d, *J* = 8.7 Hz, 1 H),
54
55 7.53 (d, *J* = 2.7 Hz, 1 H), 7.47 – 7.36 (m, 6 H), 7.25 (dd, *J* = 8.7, 2.7 Hz, 1 H), 6.08 (ddd, *J* =
56
57
58
59
60

1
2 17.2, 10.5, 5.1 Hz, 1 H), 5.75 – 5.70 (m, 1 H), 5.43 (dt, $J = 17.2, 1.4$ Hz, 1 H), 5.27 (dt, $J =$
3
4 10.5, 1.4 Hz, 1 H), 5.14 (s, 2 H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 158.3, 148.9, 138.1,
5
6 135.7, 130.2, 129.8, 128.8, 128.5, 127.6, 120.7, 115.9, 110.3, 70.67, 69.7; HRMS (H-ESI) m/z :
7
8
9 $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{16}\text{NO}_4$ 286.1079; found 286.1080.

10
11
12
13 **Silyl Ether 43.** A solution of allylic alcohol **41** (800 mg, 4.47 mmol, 1.0 equiv) in CH_2Cl_2 (40
14
15 mL) was treated with imidazole (395 mg, 5.80 mmol, 1.3 equiv) and TBSCl (875 mg, 5.80
16
17 mmol, 1.3 equiv) at 0 °C. The resulting solution was stirred for 12 h at 25 °C and then diluted
18
19 with CH_2Cl_2 , washed with a saturated aqueous NH_4Cl solution and brine, dried over anhydrous
20
21 MgSO_4 , filtered and the solvent evaporated under reduced pressure. The residue was purified
22
23 by flash column chromatography (silica gel, 5% EtOAc in hexanes) to obtain silyl ether **43** (1.2
24
25 g, 95%) as a colourless oil: $R_f = 0.88$ (silica gel, 40% EtOAc in hexanes); ^1H NMR (400 MHz,
26
27 CDCl_3) δ (ppm) 7.74 (d, $J = 8.8$ Hz, 1 H), 7.50 (d, $J = 2.6$ Hz, 1 H), 7.47 – 7.38 (m, 5 H), 7.25
28
29 (dd, $J = 8.8, 2.7$ Hz, 1 H), 5.98 (ddd, $J = 17.0, 10.3, 5.0$ Hz, 1 H), 5.84 (dt, $J = 5.0, 1.4$ Hz, 1
30
31 H), 5.35 (dt, $J = 17.0, 1.6$ Hz, 1 H), 5.13 (s, 2 H), 5.09 (dt, $J = 10.3, 1.6$ Hz, 1 H), 0.92 (s, 9 H),
32
33 0.13 (s, 3 H), 0.09 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 157.8, 147.7, 139.7, 135.8,
34
35 131.6, 129.8, 128.8, 128.4, 127.6, 120.9, 113.9, 109.3, 70.6, 69.9, 25.8, 18.3, -3.5; HRMS (H-
36
37 ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{30}\text{NO}_4\text{Si}$ 400.1944; found 400.1958.
38
39
40
41
42
43
44

45
46 **Benzyloxymethyl Acetal 45.** To a solution of allylic alcohol **41** (460 mg, 1.61 mmol, 1.0 equiv)
47
48 in CH_2Cl_2 (15 mL) was added DIPEA (1.12 mL, 6.45 mmol, 4.0 equiv) and BOMCl (1.2 mL,
49
50 6.45 mmol, 4.0 equiv) at 0 °C and the mixture was stirred at 25 °C for 15 h. After this time, the
51
52 reaction was quenched by addition of a saturated aqueous Na_2CO_3 solution and the crude
53
54 mixture was stirred for 30 min. Then, the aqueous phase was extracted with CH_2Cl_2 and the
55
56 organic phase washed with brine, dried over anhydrous MgSO_4 , filtered and the solvent
57
58
59
60

1
2 evaporated under reduced pressure. The resulting residue was purified by flash column
3
4 chromatography (silica gel, 5% EtOAc in hexanes) to obtain benzyloxymethyl acetal **45** (528
5
6 mg, 88%) as a pale yellow oil: $R_f = 0.56$ (silica gel, 20% EtOAc in hexanes); ^1H NMR (400
7
8 MHz, CDCl_3) δ (ppm) 7.65 (d, $J = 8.8$ Hz, 1 H), 7.49 (d, $J = 2.7$ Hz, 1 H), 7.43 – 7.28 (m, 10
9
10 H), 7.22 (dd, $J = 8.8, 2.7$ Hz, 1 H), 5.95 (ddd, $J = 17.1, 10.3, 6.0$ Hz, 1 H), 5.79 (d, $J = 6.1$ Hz,
11
12 1 H), 5.35 (dt, $J = 17.2, 1.4$ Hz, 1 H), 5.23 (dt, $J = 10.4, 1.3$ Hz, 1 H), 5.11 (s, 2 H), 4.91 – 4.77
13
14 (m, 2 H), 4.71 (d, $J = 6.9$ Hz, 1 H), 4.62 – 4.51 (m, 2 H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm)
15
16 158.2, 148.9, 137.6, 136.8, 135.8, 129.9, 128.8, 128.5, 128.4, 128.4, 127.9, 127.7, 127.5, 120.6,
17
18 117.0, 109.8, 92.6, 73.4, 70.7, 69.8; HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{24}\text{NO}_5$
19
20 406.1655; found 406.1651.
21
22
23
24
25
26

27 **Aniline 46.** To a solution of benzyloxymethyl acetal **45** (480 mg, 1.18 mmol, 1.0 equiv) in
28
29 EtOH (10 mL) was added a solution of NH_4Cl (317 mg, 5.92 mmol, 5.0 equiv) in water (7.5
30
31 mL) followed by Zn dust (1.2 g, 17.76 mmol, 15.0 equiv) in twelve portions of ~100 mg each
32
33 over 30 min at 25 °C. The mixture was stirred at this temperature for 12 h and then the reaction
34
35 mixture was diluted with CH_2Cl_2 and water, filtered and rinsed with CH_2Cl_2 . The filtrate was
36
37 diluted with water and extracted with CH_2Cl_2 , and the organic phase washed with brine, dried
38
39 over anhydrous MgSO_4 , filtered and the solvent evaporated under reduced pressure. The
40
41 resulting residue was purified by flash column chromatography (silica gel, 15% EtOAc in
42
43 hexanes) to obtain aniline **46** (351 mg, 79%) as a pale yellow oil: $R_f = 0.35$ (silica gel, 30%
44
45 EtOAc in hexanes); ^1H NMR (400 MHz, CDCl_3) δ (ppm) 7.42 – 7.29 (m, 10 H), 7.01 (d, $J =$
46
47 8.4 Hz, 1 H), 6.35 (dd, $J = 8.3, 2.5$ Hz, 1 H), 6.29 (d, $J = 2.5$ Hz, 1 H), 6.12 (ddd, $J = 17.2, 10.4,$
48
49 5.7 Hz, 1 H), 5.33 (dt, $J = 17.3, 1.6$ Hz, 1 H), 5.25 (dt, $J = 10.4, 1.6$ Hz, 1 H), 5.16 (dt, $J = 5.7,$
50
51 1.5 Hz, 1 H), 5.02 (s, 2 H), 4.84 – 4.76 (m, 2 H), 4.67 – 4.62 (m, 2 H), 4.16 (bs, 2 H); ^{13}C NMR
52
53 (100 MHz, CDCl_3) δ (ppm) 159.8, 146.7, 137.8, 137.2, 136.5, 130.6, 128.5, 128.4, 127.9, 127.9,
54
55
56
57
58
59
60

1
2 127.7, 127.4, 116.3, 104.2, 102.9, 91.9, 78.1, 77.2, 69.9, 69.8; HRMS (H-ESI) m/z : $[M + H]^+$
3
4 calcd for $C_{24}H_{26}NO_3$ 376.1913; found 376.1901.
5
6
7

8
9 **Diolefin 47.** A solution of the aniline **46** (50 mg, 0.13 mmol, 1.0 equiv) and acid **36** (30 mg,
10 0.13 mmol, 1.0 equiv) in dry DMF (7 mL) was treated with HATU (50 mg, 0.13 mmol, 1.0
11 equiv) and DIPEA (22 μ L, 0.13 mmol, 1.0 equiv) and the resulting solution was stirred at 25
12 $^{\circ}$ C for 12 h. After this time, a saturated aqueous NH_4Cl solution was added and the organic
13 layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic
14 layers were washed with brine, dried over anhydrous $MgSO_4$, filtered and the solvent
15 evaporated under reduced pressure. The crude product was purified by flash column
16 chromatography (silica gel, 30% EtOAc in hexanes) to obtain diolefin **47** (57 mg, 75%, 1:1
17 mixture of diastereoisomers) as a white solid. Data assigned for the mixture of diastereoisomers:
18 R_f = 0.81 (silica gel, 80% EtOAc in hexanes); mp = 90-91 $^{\circ}$ C; 1H NMR (400 MHz, $CDCl_3$) δ
19 (ppm) 8.89 (d, J = 16.4 Hz, 1 H), 7.98 (d, J = 2.5 Hz, 1 H), 7.47 – 7.27 (m, 11 H), 7.08 (dd, J =
20 8.5, 1.8 Hz, 1 H), 6.70 (ddd, J = 8.5, 2.6, 1.2 Hz, 1 H), 6.00 (ddd, J = 18.5, 9.3, 4.1 Hz, 1 H),
21 5.83 (dddd, J = 12.6, 8.8, 6.1, 4.7 Hz, 1 H), 5.30 – 5.20 (m, 3 H), 5.12 – 4.99 (m, 5 H), 4.80
22 (ddd, J = 15.5, 11.0, 6.7 Hz, 2 H), 4.67 (dd, J = 14.2, 12.2 Hz, 1 H), 4.59 – 4.54 (m, 2 H), 2.44
23 – 2.37 (m, 2 H), 2.36 – 2.29 (m, 2 H), 1.45 – 1.38 (m, 3 H); ^{13}C NMR (100 MHz, $CDCl_3$) δ
24 (ppm) 176.3, 171.9, 171.9, 170.5, 170.4, 159.4, 137.5, 137.4, 137.2, 136.9, 136.8, 136.4, 136.4,
25 130.4, 128.6, 128.6, 128.5, 128.1, 128.1, 128.0, 127.6, 120.2, 120.2, 116.8, 116.8, 115.8, 115.7,
26 115.6, 111.1, 111.0, 108.6, 108.5, 92.2, 92.0, 78.2, 78.2, 70.2, 70.1, 49.8, 49.7, 38.6, 35.7, 33.0,
27 29.4, 28.7, 19.1, 18.9; HRMS (H-ESI) m/z : $[M + H]^+$ calcd for $C_{34}H_{40}N_3O_6$ 586.2917; found
28 586.2921.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Macrocycle 48. Diolefin **47** (15 mg, 0.03 mmol, 1.0 equiv), Hoveyda-Grubbs 2nd generation catalyst (1.6 mg, 0.003 mmol, 0.10 equiv) and *p*-benzoquinone (1.0 mg, 0.003 mmol, 0.10 equiv) were dissolved in degassed CH₂Cl₂ (2 mL, 0.02 M) and the reaction mixture was heated at 40 °C for 15 h. After this time, the solvent was removed under reduced pressure and the resulting crude product was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes → 60% EtOAc in hexanes) to obtain macrocycle **48** (12 mg, 84%, 1:1 mixture of diastereoisomers) as a white solid. Data assigned for the mixture of diastereoisomers: R_f = 0.21 (silica gel, 80% EtOAc in hexanes); mp = 207-208 °C; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.81 (bs, 1 H), 8.53 (bs, 1 H), 8.51 (d, *J* = 2.6 Hz, 1 H), 8.35 (d, *J* = 2.6 Hz, 1 H), 7.46 – 7.28 (m, 23 H), 7.04 (d, *J* = 8.4 Hz, 1 H), 6.70 (dd, *J* = 8.5, 2.6 Hz, 1 H), 6.61 (dd, *J* = 8.3, 2.6 Hz, 1 H), 6.20 – 6.11 (m, 1 H), 6.08 – 5.98 (m, 2 H), 5.82 – 5.72 (m, 2 H), 5.60 (dd, *J* = 15.4, 5.7 Hz, 1 H), 5.20 – 5.16 (m, 1 H), 5.15 – 5.10 (m, 1 H), 5.07 (s, 4 H), 4.91 – 4.74 (m, 4 H), 4.71 – 4.63 (m, 4 H), 4.60 (d, *J* = 7.5 Hz, 2 H), 4.52 – 4.43 (m, 2 H), 2.51 (dd, *J* = 9.1, 4.1 Hz, 4 H), 2.39 – 2.20 (m, 4 H), 1.54 (d, *J* = 7.2 Hz, 3 H), 1.49 (d, *J* = 7.4 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 172.7, 172.7, 172.2, 170.4, 170.3, 169.5, 159.8, 159.2, 138.7, 138.1, 137.7, 136.9, 136.9, 132.4, 132.3, 132.0, 131.6, 128.7, 128.6, 128.5, 128.5, 128.5, 128.1, 127.9, 127.9, 127.9, 127.9, 127.8, 127.7, 127.6, 127.6, 127.5, 119.8, 118.3, 110.7, 109.9, 106.9, 106.7, 91.5, 90.9, 75.9, 74.5, 69.9, 69.9, 69.7, 69.5, 51.8, 51.5, 50.9, 36.9, 36.4, 30.2, 29.7, 29.6, 17.9, 16.5; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₃₂H₃₆N₃O₆ 558.2604; found 558.2615.

Acid 49. A 5 mL polypropylene syringe fitted with polyethylene porous disk charged with 2-chlorotriyl chloride (CTC) resin (363 mg, L=1.3 mmol/g, 0.47 mmol, 1.0 equiv), was loaded with a solution of Fmoc-D-Ala-OH (**34**) (441 mg, 1.42 mmol, 3.0 equiv) and DIPEA (0.29 mL, 1.65 mmol, 3.5 equiv) in dry DMF (3 mL). The resulting suspension was shaken at 280 rpm for 30 h, then the solution was unloaded and the resin was washed by shaking with dry DMF (5 x

3 mL). The resulting yellow resin was used in the subsequent step. The polypropylene syringe loaded with the yellow resin was treated with a solution of 20% piperidine in DMF (3 x 3 mL x 10 min at 280 rpm). After the last run, the resin was washed with dry DMF (5 x 3 mL) and loaded with a solution of Fmoc-Gly-OH (**35**) (281 mg, 0.94 mmol, 2.0 equiv), HOBt (128 mg, 0.94 mmol, 2.0 equiv) and DIC (0.18 mL, 1.18 mmol, 2.5 equiv) in dry DMF (3 mL). The resulting suspension was shaken at 280 rpm for 24 h, and then the solution was unloaded and the resin washed with dry DMF (5 x 3 mL). The resulting yellow resin was used in the next step. To a 5 mL polypropylene syringe fitted with polyethylene porous disk and loaded with the Fmoc protected dipeptide resin was added a solution of 20% piperidine in DMF (3 x 3 mL x 10 min at 280 rpm). After the last run, the resin was washed with dry DMF (5 x 3 mL) and treated with a solution of the acid **14** (231 mg, 0.94 mmol, 2.0 equiv), HOBt (127 mg, 0.94 mmol, 2.0 equiv) and DIC (0.18 mL, 1.18 mmol, 2.5 equiv) in dry DMF (3 mL). The resulting suspension was shaken at 280 rpm for 24 h, and then the solution was unloaded and the resin washed with dry DMF (5 x 3 mL). The resulting yellow resin was treated with a solution of CH₂Cl₂/AcOH/TFE (7:2:1, 3 mL) for 30 min. After that, the solution was collected and the resin washed with CH₂Cl₂ (2 x 3 mL). All the collected organic solvents were evaporated under reduced pressure and the resulting acid **49** (90 mg, 84% overall yield from CTC resin) was obtained as a colorless solid which not required further purification: $R_f = 0.30$ (silica gel, 10% MeOH in CH₂Cl₂); $[\alpha]_D^{25} = -5.44$ (c 0.08, CH₂Cl₂); mp = 92-93 °C; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.20 (d, $J = 5.7$ Hz, 1 H), 5.76 (ddd, $J = 17.2, 10.4, 6.8$ Hz, 1 H), 5.20 (d, $J = 17.1$ Hz, 1 H), 5.15 (d, $J = 10.5$ Hz, 1 H), 4.61 – 4.47 (m, 1 H), 4.17 (d, $J = 6.5$ Hz, 1 H), 4.08 (dd, $J = 16.6, 5.7$ Hz, 1 H), 3.86 (dd, $J = 16.6, 4.8$ Hz, 1 H), 2.41 (p, $J = 6.9$ Hz, 1 H), 1.42 (d, $J = 7.0$ Hz, 3 H), 1.11 (d, $J = 7.1$ Hz, 3 H), 0.86 (s, 9 H), 0.03 (s, 3 H), 0.02 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 175.9, 168.8, 163.2, 138.8, 116.6, 76.0, 47.8, 42.9, 36.8, 25.8, 18.1,

1
2 18.0, 14.7, -4.3, -5.1; HRMS (H-ESI) m/z : $[M + H]^+$ calcd for $C_{17}H_{33}N_2O_5Si$ 373.2159; found
3
4 373.2164.
5

6
7
8
9 **Diolefin 51.** To a solution of aniline **30** (64 mg, 0.43 mmol, 1.0 equiv) and acid **49** (160 mg,
10 043 mmol, 1.3 equiv) in DMF (10 mL) was added HATU (163 mg, 0.43 mmol, 1.0 equiv) and
11 DIPEA (0.10 mL, 0.43 mmol, 1.0 equiv) at 0 °C and the mixture was stirred for 12 h at 25 °C.
12
13 After this time, a saturated aqueous NH_4Cl solution was added and the organic layer was
14 separated. The aqueous phase was extracted with EtOAc, and the combined organic layers were
15 washed with brine, dried over anhydrous $MgSO_4$, filtered and the solvent evaporated under
16 reduced pressure. The crude product was purified by flash column chromatography (silica gel,
17 25% EtOAc in hexanes \rightarrow 100% EtOAc) to obtain diolefin **51** (60 mg, 36%, 1:1 mixture of
18 diastereoisomers) as a white foam. Data assigned for the mixture of diastereoisomers: R_f = 0.23
19 (silica gel, 100% EtOAc); 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 7.28 – 7.19 (m, 2 H), 7.17 –
20 7.10 (m, 1 H), 7.05 (t, J = 7.3 Hz, 1 H), 6.14 – 5.96 (m, 1 H), 5.78 – 5.61 (m, 1 H), 5.32 – 5.06
21 (m, 5 H), 4.43 – 4.25 (m, 1 H), 4.18 – 4.07 (m, 1 H), 3.99 (s, 1 H), 3.69 – 3.55 (m, 1 H), 2.44
22 (s, 1 H), 2.35 – 2.22 (m, 1 H), 1.36 (d, J = 5.7 Hz, 3 H), 1.00 – 0.94 (m, 3 H); ^{13}C NMR (100
23 MHz, $CDCl_3$) δ (ppm) 176.9, 176.5, 171.6, 171.2, 170.7, 170.5, 138.1, 137.9, 137.8, 136.1,
24 131.4, 131.1, 128.6, 128.5, 128.2, 128.1, 124.8, 124.8, 122.6, 122.3, 118.4, 118.0, 116.7, 116.2,
25 74.9, 74.3, 60.5, 50.5, 49.5, 46.8, 46.8, 30.7, 29.7, 17.4, 17.3, 13.8, 13.5; HRMS (H-ESI) m/z :
26 $[M + H]^+$ calcd for $C_{20}H_{28}N_3O_5$ 390.2029; found 390.2037.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Ketone 53.** To a solution of diolefin **32** (27 mg, 0.08 mmol, 1.0 equiv) in CH_2Cl_2 (15 mL) was
51 added MnO_2 (131 mg, 1.50 mmol, 20.0 equiv) and the dark solution was stirred at 25 °C for 48
52 h. The mixture was filtered through a pad of celite and rinsed with CH_2Cl_2 . The solvent was
53 evaporated under reduced pressure to obtain ketone **53** (20 mg, 75%) as a white solid which did
54
55
56
57
58
59
60

not require purification: $R_f = 0.43$ (silica gel, 100% EtOAc); $[\alpha]_D^{25} = -6.98$ (c 0.09, CH_2Cl_2); mp = 111-112 °C; ^1H NMR (400 MHz, CDCl_3) δ (ppm) 11.91 (bs, 1 H), 8.72 (dd, $J = 8.5, 1.0$ Hz, 1 H), 7.90 (dd, $J = 8.0, 1.6$ Hz, 1 H), 7.59 (ddd, $J = 8.6, 7.5, 1.4$ Hz, 1 H), 7.26 – 7.15 (m, 2 H), 7.04 (d, $J = 7.2$ Hz, 1 H), 6.73 (t, $J = 4.9$ Hz, 1 H), 6.42 (dd, $J = 16.9, 1.6$ Hz, 1 H), 5.98 (dd, $J = 10.6, 1.6$ Hz, 1 H), 5.91 – 5.77 (m, 1 H), 5.08 (ddd, $J = 17.1, 3.2, 1.6$ Hz, 1 H), 5.01 (ddd, $J = 2.9, 2.4, 1.2$ Hz, 1 H), 4.67 (p, $J = 7.2$ Hz, 1 H), 4.32 (dd, $J = 16.8, 5.8$ Hz, 1 H), 4.06 (dd, $J = 16.8, 4.8$ Hz, 1 H), 2.45 – 2.35 (m, 4 H), 1.54 (d, $J = 7.2$ Hz, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 194.2, 172.9, 171.3, 169.2, 140.7, 136.9, 135.3, 133.0, 131.3, 131.0, 122.9, 122.5, 121.0, 115.8, 50.4, 43.3, 35.5, 29.4, 18.2; HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{24}\text{N}_3\text{O}_4$ 358.1767; found 358.1789.

Dipeptide 61. To a solution of aniline **60**²³ (200 mg, 1.68 mmol, 1.0 equiv) and Boc-Gly-D-Ala-OH (**21**) (413 mg, 1.68 mmol, 1.0 equiv) in DMF (10 mL) was added HATU (960 mg, 2.52 mmol, 1.5 equiv) and DIPEA (0.30 mL, 1.68 mmol, 1.0 equiv) and the mixture was stirred for 12 h at 25 °C. After this time, the reaction mixture was diluted with CH_2Cl_2 and washed sequentially with 1 N HCl and saturated aqueous NaHCO_3 solution. The organic layer was separated, washed with brine and dried over anhydrous MgSO_4 , filtered and the solvent evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 30% EtOAc in hexanes) to obtain dipeptide **61** (455 mg, 78%) as a white solid: $R_f = 0.52$ (silica gel, 100% EtOAc); $[\alpha]_D^{25} = -6.36$ (c 0.06, CH_2Cl_2); mp = 84-85 °C; ^1H NMR (400 MHz, CDCl_3) δ (ppm) 8.13 (bs, 1 H), 7.78 (d, $J = 8.1$ Hz, 1 H), 7.45 (d, $J = 7.8$ Hz, 1 H), 7.15 (t, $J = 7.5$ Hz, 1 H), 6.85 – 6.79 (m, 1 H), 6.76 (d, $J = 9.1$ Hz, 1 H), 5.68 (dd, $J = 17.4, 1.2$ Hz, 1 H), 5.43 (dd, $J = 11.0, 1.2$ Hz, 1 H), 5.12 (bs, 1 H), 4.66 (q, $J = 7.1$ Hz, 1 H), 3.92 – 3.77 (m, 2 H), 1.50 (d, $J = 7.0$ Hz, 3 H), 1.44 (s, 9 H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm) 170.4, 170.0, 156.1, 136.9, 136.2, 131.1, 130.1, 127.2, 125.7, 123.9, 116.5, 49.5, 38.6,

1
2 36.1, 28.2, 17.7; HRMS (H-ESI) m/z : $[M + H]^+$ calcd for $C_{18}H_{26}N_3O_4$ 348.1923; found
3
4 348.1921.
5
6
7

8
9 **Diolefin 63.** Dipeptide **61** (152 mg, 0.44 mmol, 1.0 equiv) in CH_2Cl_2 (25 mL) was treated with
10
11 TFA (2.2 mL) in exactly the same manner as previously described for synthesis of **24**. A
12
13 solution of the ammonium salt and acid **62**^{10,24} (50 mg, 0.44 mmol, 1.0 equiv), in DMF (15 mL)
14
15 was treated with HATU (167 mg, 0.44 mmol, 1.0 equiv) and DIPEA (0.23 mL, 1.31 mmol, 3.0
16
17 equiv) and the resulting reaction mixture was stirred at 25 °C for 12 h. After this time, a saturated
18
19 aqueous NH_4Cl solution was added and the organic layer was separated. The aqueous phase
20
21 was extracted with EtOAc, and the combined organic layers were washed with brine and dried
22
23 over anhydrous $MgSO_4$, filtered and the solvent evaporated under reduced pressure. The crude
24
25 product was purified by flash column chromatography (silica gel, $CH_2Cl_2 \rightarrow 2\%$ MeOH in
26
27 CH_2Cl_2) to obtain diolefin **63** (150 mg, 92% over two steps) as a white solid: $R_f = 0.60$ (silica
28
29 gel, 10% MeOH in CH_2Cl_2); $[\alpha]_D^{25} = -5.43$ (c 0.07, CH_2Cl_2); mp = 104-105 °C; 1H NMR (400
30
31 MHz, $CDCl_3$) δ (ppm) 8.34 (bs, 1 H), 7.67 – 7.57 (m, 1 H), 7.46 (d, $J = 7.6$ Hz, 1 H), 7.26 –
32
33 7.13 (m, 2 H), 6.82 – 6.71 (m, 1 H), 6.68 (t, $J = 7.6$ Hz, 1 H), 6.46 (bs, 1 H), 5.81 (td, $J = 16.9$,
34
35 7.7 Hz, 1 H), 5.67 (dd, $J = 17.4$, 1.1 Hz, 1 H), 5.42 – 5.34 (m, 2 H), 5.18 – 5.12 (m, 1 H), 4.67
36
37 – 4.51 (m, 1 H), 4.25 (dd, $J = 16.7$, 7.3 Hz, 1 H), 3.79 – 3.62 (m, 2 H), 3.14 (qd, $J = 7.3$, 4.4
38
39 Hz, 2 H), 2.17 (dd, $J = 13.7$, 8.2 Hz, 1 H), 1.42 (d, $J = 6.7$ Hz, 3 H), 1.39 (d, $J = 6.6$ Hz, 3 H);
40
41 ^{13}C NMR (100 MHz, $CDCl_3$) δ (ppm) 176.1, 171.2, 170.2, 133.5, 131.8, 128.3, 126.4, 126.1,
42
43 126.0, 124.5, 124.1, 119.0, 117.5, 73.3, 55.6, 43.5, 39.2, 18.6, 17.2, 12.4. HRMS (H-ESI) m/z :
44
45 $[M + H]^+$ calcd for $C_{20}H_{28}N_3O_4$ 374.2080; found 374.2072.
46
47
48
49
50
51
52
53

54
55 **Styryl 65.** To a solution of iodonitrobenzene **18** (2.7 g, 7.60 mmol, 1.0 equiv) and $Pd[PPh_3]_4$
56
57 (1.3 g, 1.14 mmol, 0.15 equiv) in DMF (10 mL) was added dropwise tri-*n*-butyl(vinyl)tin (2.7
58
59
60

1 mL, 9.12 mmol, 1.2 equiv). The solution was then heated at 60 °C for 48 h. After this time, the mixture was diluted with Et₂O and water. The organic layer was separated and washed with water four times, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 2% EtOAc in Hexanes) to obtain styryl **65** (1.4 g, 74%) as a yellow oil: *R_f* = 0.51 (silica gel, 20% EtOAc in hexanes); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.54 (dd, *J* = 10.3, 5.7 Hz, 2 H), 7.46 – 7.34 (m, 5 H), 7.20 (ddd, *J* = 8.7, 2.7, 0.6 Hz, 1 H), 7.11 (ddd, *J* = 11.5, 10.9, 5.5 Hz, 1 H), 5.65 (dd, *J* = 17.3, 1.0 Hz, 1 H), 5.40 (dd, *J* = 11.0, 1.0 Hz, 1 H), 5.13 (s, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 158.4, 135.7, 132.0, 129.5, 128.8, 128.7, 128.5, 127.6, 126.1, 120.8, 117.4, 109.8, 70.7; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₁₅H₁₄NO₃ 256.0974; found 256.0981.

Aniline 66. To a solution of styryl **65** (550 mg, 2.16 mmol, 1.0 equiv) in EtOH (20 mL) was added a solution of NH₄Cl (576 mg, 10.77 mmol, 5.0 equiv) in water (14 mL) followed by Zn dust (2.1 g, 32.32 mmol, 15.0 equiv) in ten portions of ~200 mg each over 30 min at 25 °C. The mixture was stirred at this temperature for 12 h and then the reaction mixture was diluted with CH₂Cl₂ and water, filtered and rinsed with CH₂Cl₂. The filtrate was diluted with water and extracted with CH₂Cl₂, and the organic phase washed with brine, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The resulting residue was purified by flash column chromatography (silica gel, 10% EtOAc in hexanes) to obtain aniline **66** (413 mg, 85%) as a yellow oil: *R_f* = 0.47 (silica gel, 30% EtOAc in hexanes); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.45 – 7.31 (m, 5 H), 7.27 – 7.21 (m, 1 H), 6.71 (dd, *J* = 17.4, 11.1 Hz, 1 H), 6.44 (dd, *J* = 8.5, 2.4 Hz, 1 H), 6.32 (d, *J* = 2.5 Hz, 1 H), 5.54 (dd, *J* = 17.4, 1.5 Hz, 1 H), 5.22 (dd, *J* = 11.0, 1.5 Hz, 1 H), 5.04 (s, 2 H), 3.78 (bs, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm)

159.6, 144.9, 137.2, 132.2, 128.6, 128.5, 127.9, 127.4, 117.5, 113.8, 105.7, 102.3, 69.9; HRMS (H-ESI) m/z : $[M + H]^+$ calcd for $C_{15}H_{16}NO$ 226.1232; found 226.1229.

Dipeptide 67. To a solution of aniline **66** (340 mg, 1.51 mmol, 1.0 equiv) and Boc-Gly-D-Ala-OH (**21**) (483 mg, 1.962 mmol, 1.0 equiv) in DMF (5 mL) was added HATU (861 mg, 2.26 mmol, 1.5 equiv) and DIPEA (0.5 mL, 3.02 mmol, 1.0 equiv) and the mixture was stirred for 12 h at 25 °C. After this time, a saturated aqueous NH_4Cl solution was added and the organic layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous $MgSO_4$, filtered and the solvent evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 15% EtOAc in hexanes \rightarrow 35% EtOAc in hexanes) to obtain dipeptide **67** (554 mg, 81%) as a yellow foam: $R_f = 0.64$ (silica gel, 100% EtOAc); $[\alpha]_D^{25} = -3.96$ (c 0.15, CH_2Cl_2); 1H NMR (400 MHz, $CDCl_3$) δ (ppm) 8.30 (d, $J = 13.1$ Hz, 1 H), 7.60 (bs, 1 H), 7.46 – 7.30 (m, 7 H), 6.78 (d, $J = 2.7$ Hz, 1 H), 6.76 – 6.69 (m, 1 H), 5.56 (d, $J = 17.3$ Hz, 1 H), 5.31 (d, $J = 11.6$ Hz, 1 H), 5.18 (bs, 1 H), 5.04 (s, 2 H), 4.68 (p, $J = 7.1$ Hz, 1 H), 3.88 – 3.79 (m, 2 H), 1.47 (d, $J = 6.3$ Hz, 3 H), 1.43 (s, 9 H); ^{13}C NMR (100 MHz, $CDCl_3$) δ (ppm) 170.2, 170.1, 158.8, 156.2, 136.8, 135.1, 131.4, 128.5, 127.9, 127.6, 123.2, 120.4, 116.0, 112.8, 109.1, 80.7, 70.1, 49.6, 44.4, 28.3, 17.5; HRMS (H-ESI) m/z : $[M + H]^+$ calcd for $C_{25}H_{32}N_3O_5$ 454.2342; found 454.2340.

Diolefin 69. Dipeptide **67** (70 mg, 0.15 mmol, 1.0 equiv) in CH_2Cl_2 (10 mL) was treated with TFA (2.2 mL) in exactly the same manner as previously described for synthesis of **24**. A solution of the resulting ammonium salt and hexenoic acid **68** (18 μ L, 0.15 mmol, 1.0 equiv), in CH_2Cl_2 (15 mL) was treated with BOP (66 mg, 0.15 mmol, 1.0 equiv) and DIPEA (77 μ L, 0.45 mmol, 3.0 equiv) and the resulting solution was stirred at 25 °C for 12 h. After this time, a

1 saturated aqueous NH_4Cl solution was added and the organic layer was separated. The aqueous
2 phase was extracted with EtOAc, and the combined organic layers were washed with brine,
3 dried over anhydrous MgSO_4 , filtered and the solvent evaporated under reduced pressure. The
4 resulting residue was purified by flash column chromatography (silica gel, 30% EtOAc in
5 hexanes) to obtain diolefin **69** (51 mg, 74% over two steps) as a white solid: $R_f = 0.45$ (silica
6 gel, 100% EtOAc); $[\alpha]_D^{25} = -9.02$ (c 0.11, CH_2Cl_2); mp = 82-83 °C ; ^1H NMR (400 MHz,
7 CDCl_3) δ (ppm) 8.24 (bs, 1 H), 7.58 (bs, 1 H), 7.44 – 7.30 (m, 6 H), 7.06 (s, 1 H), 6.80 – 6.75
8 (m, 1 H), 6.72 (dd, $J = 16.1, 9.7$ Hz, 1 H), 6.34 (s, 1 H), 5.74 (ddt, $J = 17.0, 10.0, 6.8$ Hz, 1 H),
9 5.56 (d, $J = 17.3$ Hz, 1 H), 5.29 (d, $J = 11.0$ Hz, 1 H), 5.05 – 5.00 (m, 3 H), 5.00 – 4.93 (m, 1
10 H), 4.71 – 4.61 (m, 1 H), 4.06 – 3.93 (m, 2 H), 2.23 (td, $J = 7.8, 1.7$ Hz, 2 H), 2.10 – 2.02 (m,
11 2 H), 1.77 – 1.68 (m, 2 H), 1.48 (d, $J = 7.0$ Hz, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ (ppm)
12 173.8, 170.1, 169.4, 158.9, 137.7, 136.7, 135.1, 131.4, 128.6, 128.0, 127.6, 127.6, 123.0, 116.1,
13 115.5, 112.7, 109.0, 70.1, 49.8, 43.3, 35.4, 33.1, 24.5, 17.6; HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd
14 for $\text{C}_{26}\text{H}_{32}\text{N}_3\text{O}_4$ 450.2393; found 450.2391.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36 **Macrocycle 70.** Diolefin **69** (19 mg, 0.08 mmol, 1.0 equiv), Hoveyda-Grubbs 2nd generation
37 catalyst (3 mg, 0.004 mmol, 0.10 equiv) and *p*-benzoquinone (1.0 mg, 0.004 mmol, 0.10 equiv)
38 were dissolved in degassed CH_2Cl_2 (2 mL, 0.02 M) and the reaction mixture was heated at 40
39 °C for 12 h. After this time, the solvent was removed under reduced pressure and the resulting
40 crude product was purified by flash column chromatography (silica gel, $\text{CH}_2\text{Cl}_2 \rightarrow 3\%$ MeOH
41 in CH_2Cl_2) to obtain macrocycle **70** (6.1 mg, 43%) as a white solid: $R_f = 0.76$ (silica gel, 10%
42 MeOH in CH_2Cl_2); $[\alpha]_D^{25} = -5.32$ (c 0.09, MeOH); mp = 196-197 ; ^1H NMR (400 MHz,
43 $\text{DMSO}-d_6$) δ (ppm) 8.54 (bs, 1 H), 8.40 (t, $J = 5.9$ Hz, 1 H), 7.46 – 7.35 (m, 5 H), 7.32 (d, $J =$
44 7.0 Hz, 1 H), 7.29 (d, $J = 2.5$ Hz, 1 H), 7.06 (d, $J = 8.5$ Hz, 1 H), 6.77 (dd, $J = 8.4, 2.6$ Hz, 1
45 H), 5.42 (dt, $J = 15.8, 5.2$ Hz, 1 H), 5.04 (s, 2 H), 4.40 – 4.31 (m, 1 H), 3.85 (dd, $J = 14.8, 6.3$
46 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
47 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
48 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
49 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
50 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
51 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
52 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
53 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
54 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
55 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
56 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
57 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
58 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
59 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
60 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
61 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
62 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
63 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
64 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
65 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
66 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
67 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
68 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
69 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
70 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
71 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
72 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
73 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
74 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
75 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
76 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
77 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
78 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
79 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
80 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
81 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
82 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
83 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
84 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
85 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
86 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
87 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
88 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
89 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
90 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
91 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
92 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
93 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
94 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
95 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
96 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
97 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
98 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
99 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
100 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
101 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
102 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
103 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
104 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
105 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
106 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
107 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
108 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
109 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
110 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
111 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
112 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
113 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
114 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
115 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
116 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
117 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
118 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
119 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
120 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
121 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
122 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
123 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
124 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
125 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
126 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
127 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
128 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
129 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
130 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
131 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
132 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
133 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
134 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
135 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
136 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
137 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
138 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
139 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
140 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
141 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
142 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
143 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
144 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
145 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
146 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
147 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
148 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
149 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
150 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
151 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
152 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1
153 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J = 14.8, 6.3$ Hz, 1 H), 3.85 (dd, $J =$

1
2 Hz, 1 H), 3.45 (dd, $J = 14.8, 5.6$ Hz, 1 H), 3.20 (dd, $J = 15.5, 5.1$ Hz, 1 H), 3.03 (dd, $J = 15.5,$
3
4 5.2 Hz, 1 H), 2.34 – 2.04 (m, 4 H), 1.30 (d, $J = 7.1$ Hz, 3 H); ^{13}C NMR (100 MHz, DMSO- d_6)
5
6 δ (ppm) 173.1, 171.4, 171.1, 157.4, 137.6, 137.3, 131.6, 130.7, 128.9, 128.2, 128.1, 128.09,
7
8 128.0, 125.8, 111.8, 69.7, 49.7, 43.4, 34.7, 33.7, 27.9, 16.8; HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd
9
10 for $\text{C}_{24}\text{H}_{28}\text{N}_3\text{O}_4$ 422.2079; found 422.2073.
11
12
13
14
15

16 **Diolefin 59.** Dipeptide **67** (420 mg, 0.93 mmol, 1.0 equiv) in CH_2Cl_2 (10 mL) was treated with
17
18 TFA (4.6 mL) in exactly the same manner as previously described for synthesis of **24**. A
19
20 solution of the corresponding ammonium salt and acid **62** (174 mg, 1.20 mmol, 1.3 equiv), in
21
22 CH_2Cl_2 (15 mL) was treated with HATU (528 mg, 1.39 mmol, 1.0 equiv) and DIPEA (0.5 mL,
23
24 2.78 mmol, 3.0 equiv) and the resulting solution was stirred at 25 °C for 12 h. After this time, a
25
26 saturated aqueous NH_4Cl solution was added and the organic layer was separated. The aqueous
27
28 phase was extracted with EtOAc, and the combined organic layers were washed with brine,
29
30 dried over anhydrous MgSO_4 , filtered and the solvent evaporated under reduced pressure. The
31
32 resulting residue was purified by flash column chromatography (silica gel, 50% EtOAc in
33
34 hexanes \rightarrow 100% EtOAc) to obtain diolefin **59** (67 mg, 86% over two steps) as a white solid:
35
36 $R_f = 0.46$ (silica gel, 10% MeOH in CH_2Cl_2); $[\alpha]_D^{25} = -3.98$ (c 0.07, MeOH); mp = 88-89 °C;
37
38 ^1H NMR (400 MHz, MeOD) δ (ppm) 7.53 (d, $J = 8.7$ Hz, 1 H), 7.44 – 7.27 (m, 6 H), 7.04 (d, J
39
40 = 2.6 Hz, 1 H), 6.89 (dd, $J = 8.7, 2.6$ Hz, 1 H), 6.80 (dd, $J = 17.5, 11.1$ Hz, 1 H), 5.98 – 5.82
41
42 (m, 1 H), 5.62 (dd, $J = 17.4, 1.2$ Hz, 1 H), 5.20 (dd, $J = 11.0, 1.3$ Hz, 1 H), 5.11 (dd, $J = 18.9,$
43
44 1.7 Hz, 1 H), 5.07 (s, 2 H), 5.07 – 5.03 (m, 1 H), 4.55 – 4.47 (m, 1 H), 4.02 (d, $J = 16.9$ Hz, 1
45
46 H), 3.79 (d, $J = 16.9$ Hz, 1 H), 3.71 (td, $J = 7.3, 4.0$ Hz, 1 H), 2.48 – 2.38 (m, 2 H), 2.27 – 2.18
47
48 (m, 1 H), 1.46 (d, $J = 7.2$ Hz, 3 H), 1.11 (d, $J = 6.9$ Hz, 3 H); ^{13}C NMR (100 MHz, MeOD) δ
49
50 (ppm) 177.3, 172.7, 170.5, 163.5, 158.7, 137.1, 134.9, 134.2, 131.6, 128.1, 127.6, 127.2, 126.4,
51
52
53
54
55
56
57
58
59
60

1
2 116.5, 113.5, 112.9, 112.1, 73.1, 69.7, 42.3, 38.6, 35.6, 30.3, 16.5, 12.9; HRMS (H-ESI) m/z :
3
4 $[M + H]^+$ calcd for $C_{27}H_{34}N_3O_5$ 480.2499; found 480.2501.
5
6
7

8
9 **Diolefin 71.** To a solution of diolefin **59** (35 mg, 0.07 mmol, 1.0 equiv) in CH_2Cl_2 (5 mL) was
10 added 2,6-lutidine (20 μ L, 0.15 mmol, 2.0 equiv) at 0 °C and the mixture was stirred 10 min at
11 this temperature. After this time TBSOTf (0.03 mL, 0.15 mmol, 2.0 equiv) was added at 0 °C
12 and the mixture was stirred for 12 h at 25 °C. Then, the reaction was quenched by addition of
13 H_2O . After decantation of the organic layer, the aqueous phase was extracted with EtOAc, and
14 the combined organic layers were washed with brine, dried over anhydrous $MgSO_4$, filtered
15 and the solvent evaporated under reduced pressure. The crude product was purified by flash
16 column chromatography (silica gel, 20% EtOAc in hexanes \rightarrow 100% EtOAc) to obtain diolefin
17 **71** (31 mg, 72%) as a white solid: $R_f = 0.80$ (silica gel, 100% EtOAc); $[\alpha]_D^{25} = -6.98$ (c 0.06,
18 MeOH); mp = 96-97 °C; 1H NMR (400 MHz, MeOD) δ (ppm) 7.52 (d, $J = 8.7$ Hz, 1 H), 7.44 –
19 7.40 (m, 2 H), 7.39 – 7.33 (m, 2 H), 7.33 – 7.27 (m, 1 H), 7.06 (d, $J = 2.6$ Hz, 1 H), 6.89 (dd, J
20 = 8.7, 2.7 Hz, 1 H), 6.79 (dd, $J = 17.5, 11.1$ Hz, 1 H), 5.89 (dddd, $J = 16.5, 10.4, 8.2, 6.0$ Hz, 1
21 H), 5.62 (dd, $J = 17.5, 1.3$ Hz, 1 H), 5.19 (dd, $J = 11.0, 1.3$ Hz, 1 H), 5.11 – 5.07 (m, 1 H), 5.07
22 (s, 2 H), 5.06 – 5.03 (m, 1 H), 4.56 – 4.49 (m, 1 H), 4.07 (d, $J = 16.5$ Hz, 1 H), 3.98 – 3.89 (m,
23 1 H), 3.70 (d, $J = 16.6$ Hz, 1 H), 2.58 – 2.46 (m, 1 H), 2.40 – 2.22 (m, 2 H), 1.47 (d, $J = 7.1$ Hz,
24 3 H), 1.08 (d, $J = 7.0$ Hz, 3 H), 0.87 (s, 9 H), 0.08 (s, 3 H), 0.03 (s, 3 H); ^{13}C NMR (100 MHz,
25 MeOD) δ (ppm) 176.9, 172.6, 169.9, 158.7, 137.1, 134.9, 133.7, 131.6, 128.1, 127.5, 127.2,
26 126.4, 125.9, 116.6, 113.4, 112.9, 112.0, 73.3, 69.7, 49.4, 45.9, 42.0, 38.1, 24.9, 17.5, 16.8,
27 12.7, -5.6, -6.1; HRMS (H-ESI) m/z : $[M + H]^+$ calcd for $C_{33}H_{48}N_3O_5Si$ 594.3363; found
28 594.3367.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Macrocycle 72. Diolefin **71** (20 mg, 0.03 mmol, 1.0 equiv), Hoveyda-Grubbs 2nd generation catalyst (2 mg, 0.003 mmol, 0.10 equiv) and *p*-benzoquinone (1.0 mg, 0.003 mmol, 0.10 equiv) were dissolved in degassed CH₂Cl₂ (2 mL, 0.02 M) and the reaction mixture was heated at 40 °C for 12 h. After this time, the solvent was removed under reduced pressure and the resulting crude product was purified by flash column chromatography (silica gel, 20% EtOAc in hexanes → 60% EtOAc in hexanes) to obtain macrocycle **72** (9.0 mg, 47%) as a white solid: $R_f = 0.51$ (silica gel, 70% EtOAc in hexanes); $[\alpha]_D^{25} = -9.21$ (*c* 0.08, MeOH); mp = 205-206 °C; ¹H NMR (400 MHz, MeOD) δ (ppm) 7.44 – 7.27 (m, 6 H), 7.08 (d, *J* = 2.6 Hz, 1 H), 6.85 (dd, *J* = 8.7, 2.8 Hz, 1 H), 6.45 (d, *J* = 15.8 Hz, 1 H), 5.98 (ddd, *J* = 15.4, 7.5, 3.1 Hz, 1 H), 5.07 (s, 2 H), 4.25 (q, *J* = 7.2 Hz, 1 H), 4.13 (td, *J* = 6.6, 3.7 Hz, 1 H), 3.96 (d, *J* = 14.6 Hz, 1 H), 3.74 (d, *J* = 14.6 Hz, 1 H), 2.59 – 2.49 (m, 3 H), 1.54 (d, *J* = 7.2 Hz, 3 H), 1.15 (d, *J* = 7.2 Hz, 3 H), 0.95 (s, 9 H), 0.15 (overlap two singlets, 6 H); ¹³C NMR (100 MHz, MeOD) δ (ppm) 176.8, 171.6, 171.3, 158.2, 137.2, 134.5, 128.6, 128.1, 127.5, 127.2, 126.3, 126.2, 125.4, 113.3, 112.3, 73.4, 69.7, 50.9, 46.3, 43.3, 38.9, 24.9, 17.5, 14.6, 12.0, -5.7, -6.1; HRMS (H-ESI) *m/z*: [M + Na]⁺ calcd for C₃₁H₄₃N₃O₅SiNa 588.2870; found 588.2868.

Diolefin 73. To a solution of diolefin **59** (53 mg, 0.11 mmol, 1.0 equiv) in CH₂Cl₂ (10 mL) was added 2,6-lutidine (30 μ L, 0.28 mmol, 2.5 equiv) at 0 °C and the mixture was stirred 10 min at this temperature. After this time TESOTf (0.06 mL, 0.30 mmol, 2.5 equiv) was added at 0 °C and the mixture was stirred for 12 h at 25 °C. Then, the reaction was quenched by addition of H₂O. After decantation of the organic layer, the aqueous phase was extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 15% EtOAc in hexanes → 60% EtOAc) to obtain diolefin **73** (45 mg, 68%) as a white solid: $R_f = 0.80$ (silica gel, 100% EtOAc); $[\alpha]_D^{25} = -9.41$ (*c* 0.08,

1
2 MeOH); mp = 92-93 °C; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.53 (d, *J* = 8.7 Hz, 1 H), 7.45 –
3
4 7.40 (m, 2 H), 7.39 – 7.33 (m, 2 H), 7.31 (dt, *J* = 5.3, 2.1 Hz, 1 H), 7.06 (d, *J* = 2.6 Hz, 1 H),
5
6 6.89 (dd, *J* = 8.5, 2.4 Hz, 1 H), 6.80 (dd, *J* = 17.5, 11.0 Hz, 1 H), 5.89 (dddd, *J* = 16.5, 10.3,
7
8 8.1, 6.1 Hz, 1 H), 5.62 (dd, *J* = 17.5, 1.3 Hz, 1 H), 5.20 (dd, *J* = 11.0, 1.3 Hz, 1 H), 5.13 – 5.03
9
10 (m, 4 H), 4.53 (q, *J* = 7.0 Hz, 1 H), 4.06 (d, *J* = 16.6 Hz, 1 H), 3.97 – 3.91 (m, 1 H), 3.74 (d, *J*
11
12 = 16.5 Hz, 1 H), 2.54 – 2.44 (m, 1 H), 2.40 – 2.22 (m, 2 H), 1.47 (d, *J* = 7.1 Hz, 3 H), 1.09 (d,
13
14 *J* = 7.0 Hz, 3 H), 0.95 (t, *J* = 7.9 Hz, 9 H), 0.61 (q, *J* = 7.6 Hz, 6 H); ¹³C NMR (100 MHz,
15
16 CDCl₃) δ (ppm) 176.9, 172.7, 169.9, 158.7, 137.1, 134.9, 133.9, 131.6, 128.1, 127.5, 127.2,
17
18 126.4, 125.9, 116.6, 113.4, 112.9, 112.0, 73.4, 69.7, 49.4, 46.1, 41.9, 38.5, 16.7, 12.9, 5.9, 4.5;
19
20 HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₃₃H₄₈N₃O₅Si 594.3363; found 594.3359.
21
22
23
24
25
26

27 **Macrocycle 74.** Diolefin **73** (22 mg, 0.04 mmol, 1.0 equiv), Hoveyda-Grubbs 2nd generation
28
29 catalyst (2 mg, 0.004 mmol, 0.10 equiv) and *p*-benzoquinone (1.0 mg, 0.004 mmol, 0.10 equiv)
30
31 were dissolved in degassed CH₂Cl₂ (2 mL, 0.02 M) and the reaction mixture was heated at 40
32
33 °C for 12 h. After this time, the solvent was removed under reduced pressure and the resulting
34
35 crude product was purified by flash column chromatography (silica gel, 30% EtOAc in hexanes
36
37 → 60% EtOAc in hexanes) to obtain macrocycle **74** (11 mg, 53%) as a white solid: *R_f* = 0.28
38
39 (silica gel, 70% EtOAc in hexanes); [α]²⁵_D = – 11.08 (*c* 0.09, MeOH); mp = 198-199 °C; ¹H
40
41 NMR (400 MHz, MeOD) δ (ppm) 7.44 – 7.40 (m, 2 H), 7.39 – 7.33 (m, 3 H), 7.33 – 7.27 (m,
42
43 2 H), 7.08 (d, *J* = 2.6 Hz, 1 H), 6.85 (dd, *J* = 8.6, 2.5 Hz, 1 H), 6.46 (d, *J* = 15.7 Hz, 1 H), 6.02
44
45 – 5.93 (m, 1 H), 5.07 (s, 2 H), 4.24 (q, *J* = 7.1 Hz, 1 H), 4.14 (dd, *J* = 10.2, 6.6 Hz, 1 H), 3.95
46
47 (d, *J* = 14.6 Hz, 1 H), 3.74 (d, *J* = 14.4 Hz, 1 H), 2.65 – 2.46 (m, 3 H), 1.54 (d, *J* = 7.2 Hz, 3
48
49 H), 1.17 (d, *J* = 7.2 Hz, 3 H), 1.02 (t, *J* = 7.9 Hz, 9 H), 0.70 (q, *J* = 7.5 Hz, 6 H); ¹³C NMR (100
50
51 MHz, MeOD) δ (ppm) 176.8, 171.6, 171.3, 158.1, 137.2, 134.5, 128.7, 128.1, 127.5, 127.2,
52
53
54
55
56
57
58
59
60

1
2 126.3, 126.0, 125.4, 113.3, 112.3, 73.2, 69.9, 50.9, 46.3, 39.1, 29.3, 14.6, 12.2, 5.9, 4.4; HRMS
3
4 (H-ESI) m/z : $[M + H]^+$ calcd for $C_{31}H_{44}N_3O_5Si$ 566.3050; found 566.3067.
5
6
7

8
9 **Macrocyclic 58.** To a solution of macrocyclic **74** (5.0 mg, 0.01 mmol, 1.0 equiv) in THF (3 mL)
10 was added at 0 °C TBAF (18 μ L, 1.0 M in THF, 0.018 mmol, 2.0 equiv). After 95 min the
11 solvent was removed under reduced pressure and the crude mixture was purified by preparative
12 TLC (silica gel 60 F₂₅₄, 1 mm, 100% EtOAc) to obtain macrocyclic **58** (3.4 mg, 85%) as a white
13 solid: R_f = 0.27 (silica gel, 100% EtOAc); $[\alpha]_D^{25}$ = -7.72 (*c* 0.04, MeOH); mp = 201-202 °C;
14
15 ¹H NMR (400 MHz, MeOD) δ (ppm) 7.44 – 7.40 (m, 2 H), 7.38 – 7.32 (m, 3 H), 7.32 – 7.27
16 (m, 1 H), 7.19 (d, J = 2.6 Hz, 1 H), 6.85 (dd, J = 8.6, 2.6 Hz, 1 H), 6.41 (d, J = 15.4 Hz, 1 H),
17
18 6.00 (dt, J = 15.4, 7.4 Hz, 1 H), 5.08 (s, 2 H), 4.55 (s, 1 H), 4.45 (q, J = 7.1 Hz, 1 H), 4.06 (d, J
19 = 14.9 Hz, 1 H), 3.87 (td, J = 6.8, 2.9 Hz, 1 H), 3.72 (d, J = 14.9 Hz, 1 H), 2.56 – 2.50 (m, 3
20
21 H), 1.47 (d, J = 7.2 Hz, 3 H), 1.25 (d, J = 7.2 Hz, 3 H); ¹³C NMR (100 MHz, MeOD) δ (ppm)
22
23 176.7, 171.6, 170.7, 158.3, 137.1, 134.5, 128.9, 128.1, 127.6, 127.5, 127.2, 126.7, 125.1, 113.0,
24
25 111.3, 72.3, 69.8, 50.1, 44.9, 42.9, 39.2, 15.3, 13.5; HRMS (H-ESI) m/z : $[M + H]^+$ calcd for
26
27 $C_{25}H_{30}N_3O_5$ 452.2186; found 452.2170.
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Homoallylic Alcohol 77.** A solution of aldehyde **40** (395 mg, 1.54 mmol, 1.0 equiv) in CH₂Cl₂
42 (15 mL) was cooled to 0 °C and SnCl₄ (0.8 mL, 0.77 mmol, 0.5 equiv, 1.0 M in CH₂Cl₂) was
43 added slowly over 10 min at this temperature and then stirred for 10 min at 25 °C. Allyl
44 trimethylsilane (0.35 mL, 2.30 mmol, 1.5 equiv) was added quickly and the reaction was stirred
45 for 15 min, poured into Et₂O and after decantation the organic phase was washed with brine,
46
47 dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The
48 crude product was purified by flash column chromatography (silica gel, 5% EtOAc in Hexanes)
49
50 to obtain the homoallylic alcohol **77** (340 mg, 74%) as a yellow solid: R_f = 0.67 (silica gel, 40%
51
52
53
54
55
56
57
58
59
60

1
2 EtOAc in hexanes); mp = 74-75 °C; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.71 (d, *J* = 8.8 Hz,
3 1 H), 7.52 (d, *J* = 2.7 Hz, 1 H), 7.46 – 7.34 (m, 5 H), 7.26 – 7.23 (m, 1 H), 5.88 (dddd, *J* = 16.9,
4 10.5, 7.8, 6.4 Hz, 1 H), 5.26 – 5.19 (m, 2 H), 5.17 (t, *J* = 1.1 Hz, 1 H), 5.12 (s, 2 H), 2.67 (dddt,
5 *J* = 14.0, 6.4, 3.8, 1.3 Hz, 1 H), 2.47 – 2.34 (m, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm)
6 158.0, 148.4, 135.8, 134.2, 131.5, 129.3, 128.8, 128.4, 127.6, 120.8, 118.9, 109.9, 70.7, 68.2,
7 42.8; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₁₇H₁₈NO₄ 300.1236; found 300.1238.
8
9
10
11
12
13
14
15
16
17

18 **Benzyloxymethyl Acetal 78.** To a solution of the homoallylic alcohol **77** (226 mg, 0.76 mmol,
19 1.0 equiv) in CH₂Cl₂ (10 mL) was added DIPEA (0.52 mL, 3.02 mmol, 4.0 equiv) and BOMCl
20 (0.56 mL, 3.02 mmol, 4.0 equiv) at 0 °C and the mixture was stirred at 25 °C for 15 h. After this
21 time, the reaction was quenched by addition of saturated aqueous Na₂CO₃ solution and the
22 crude mixture was stirred for 30 min. Then, the aqueous phase was extracted with CH₂Cl₂ and
23 the organic phase washed with brine, dried over anhydrous MgSO₄, filtered and the solvent
24 evaporated under reduced pressure. The resulting residue was purified by flash column
25 chromatography (silica gel, 3% EtOAc in hexanes) to obtain benzyloxymethyl acetal **78** (280
26 mg, 88%) as a pale yellow oil: *R_f* = 0.50 (silica gel, 20% EtOAc in hexanes); ¹H NMR (400
27 MHz, CDCl₃) δ (ppm) 7.67 (d, *J* = 8.7 Hz, 1 H), 7.53 (d, *J* = 2.6 Hz, 1 H), 7.46 – 7.22 (m, 11
28 H), 5.94 (ddt, *J* = 17.1, 10.1, 7.0 Hz, 1 H), 5.35 (dd, *J* = 8.0, 4.2 Hz, 1 H), 5.15 (dd, *J* = 17.0,
29 1.7 Hz, 2 H), 5.11 (s, 2 H), 4.91 (d, *J* = 9.0 Hz, 1 H), 4.71 (dd, *J* = 21.3, 5.5 Hz, 2 H), 4.66 (s,
30 1 H), 4.59 (d, *J* = 6.9 Hz, 1 H), 4.47 (d, *J* = 11.8 Hz, 1 H), 2.67 – 2.59 (m, 1 H), 2.57 – 2.48 (m,
31 1 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 158.1, 148.9, 137.6, 135.8, 134.3, 130.3, 129.7,
32 128.8, 128.4, 128.4, 127.8, 127.7, 127.6, 120.8, 117.8, 109.7, 93.1, 73.3, 70.7, 69.8, 42.0;
33 HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₂₅H₂₆NO₅ 420.1811; found 420.1815.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Aniline 79. To a solution of benzyloxymethyl acetal **78** (280 mg, 0.67 mmol, 1.0 equiv) in EtOH (6 mL) was added a solution of NH₄Cl (179 mg, 3.34 mmol, 5.0 equiv) in water (4 mL) followed by Zn dust (655 mg, 10.01 mmol, 15.0 equiv) in seven portions of ~100 mg each over 30 min at 25 °C. The mixture was stirred at this temperature for 15 h and then the reaction mixture was diluted with CH₂Cl₂ and water, filtered and rinsed with CH₂Cl₂. The filtrate was diluted with water and extracted with CH₂Cl₂, and the organic phase washed with brine, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The resulting residue was purified by flash column chromatography (silica gel, 10% EtOAc in hexanes) to obtain aniline **79** (217 mg, 87%) as a yellow oil: *R_f* = 0.60 (silica gel, 30% EtOAc in hexanes); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.41 – 7.30 (m, 10 H), 6.94 (d, *J* = 8.4 Hz, 1 H), 6.34 (dd, *J* = 8.3, 2.5 Hz, 1 H), 6.28 (d, *J* = 2.5 Hz, 1 H), 5.81 (ddt, *J* = 17.2, 10.1, 7.0 Hz, 1 H), 5.12 (ddd, *J* = 17.1, 3.4, 1.4 Hz, 1 H), 5.05 (ddt, *J* = 10.2, 2.1, 1.0 Hz, 1 H), 5.01 (s, 2 H), 4.90 (d, *J* = 9.1 Hz, 1 H), 4.73 – 4.71 (m, 2 H), 4.67 – 4.63 (m, 1 H), 4.52 (d, *J* = 11.7 Hz, 1 H), 4.20 (bs, 2 H), 2.83 – 2.74 (m, 1 H), 2.62 – 2.53 (m, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 159.5, 146.5, 137.8, 137.2, 135.3, 130.6, 128.6, 128.4, 128.0, 127.9, 127.7, 127.5, 117.1, 116.9, 104.1, 102.9, 91.9, 77.9, 69.8, 69.7, 38.7; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₂₅H₂₈NO₃ 390.2069; found 390.2071.

Peptide 80. To a solution of aniline **79** (217 mg, 0.56 mmol, 1.0 equiv) and Fmoc-D-Ala-OH (**34**) (225 mg, 0.72 mmol, 1.3 equiv) in CH₂Cl₂ (10 mL) was added PyBOP (435 mg, 0.84 mmol, 1.5 equiv) and DIPEA (0.2 mL, 1.11 mmol, 2.0 equiv) at 0 °C and the mixture was stirred for 15 h at 25 °C. After this time, a saturated aqueous NH₄Cl solution was added and the organic layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The crude product was purified by flash column

1 chromatography (silica gel, 30% EtOAc in hexanes) to obtain peptide **80** (247 mg, 65%, 1:1
2 mixture of diastereoisomers) as a white foam. Data assigned for the mixture of
3 diastereoisomers: $R_f = 0.20$ (silica gel, 30% EtOAc in hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3)
4 δ (ppm) 9.32 (d, $J = 11.0$ Hz, 1 H), 8.03 (d, $J = 8.7$ Hz, 1 H), 7.77 (d, $J = 7.4$ Hz, 2 H), 7.61 (d,
5 $J = 6.0$ Hz, 2 H), 7.47 – 7.27 (m, 13 H), 7.21 (dd, $J = 7.2, 5.5$ Hz, 2 H), 7.02 (d, $J = 8.4$ Hz, 1
6 H), 6.69 (dd, $J = 8.4, 2.5$ Hz, 1 H), 5.72 (td, $J = 16.8, 6.9$ Hz, 1 H), 5.40 (d, $J = 6.5$ Hz, 1 H),
7 5.13 – 5.01 (m, 4 H), 4.77 – 4.64 (m, 3 H), 4.64 – 4.56 (m, $J = 11.4, 8.2$ Hz, 1 H), 4.54 – 4.45
8 (m, 1 H), 4.43 – 4.32 (m, 2 H), 4.23 (dd, $J = 14.3, 7.2$ Hz, 1 H), 2.73 – 2.61 (m, 1 H), 2.53 –
9 2.40 (m, 1 H), 1.51 – 1.42 (m, 3 H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ (ppm) 170.3, 159.1, 159.0,
10 155.8, 143.8, 141.3, 137.3, 137.2, 136.8, 134.2, 134.1, 129.9, 129.9, 128.5, 128.5, 128.4, 127.9,
11 127.9, 127.9, 127.9, 127.9, 127.8, 127.6, 127.1, 125.2, 125.0, 120.0, 117.9, 117.8, 111.1, 108.3,
12 108.1, 92.4, 78.6, 70.1, 70.0, 67.1, 51.6, 47.1, 39.9, 39.9, 18.9, 18.9; HRMS (H-ESI) m/z : $[\text{M} +$
13 $\text{H}]^+$ calcd for $\text{C}_{43}\text{H}_{43}\text{N}_2\text{O}_6$ 683.3121; found 683.3115.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34 **Dipeptide 81.** To a solution of peptide **80** (176 mg, 0.26 mmol, 1.0 equiv) in CH_2Cl_2 (5 mL)
35 was added piperidine (0.13 mL, 1.29 mmol, 5.0 equiv) and the reaction mixture was stirred at
36 25 °C for 5 h. After this time, the organic solvent was removed under reduced pressure and the
37 resulting crude product was purified by flash column chromatography (silica gel, 30% EtOAc
38 in hexanes \rightarrow 60% EtOAc in hexanes) to obtain the corresponding amine (110 mg, 93%, 1:1
39 mixture of diastereoisomers) as a white solid. Data assigned for the mixture of diastereoisomers:
40 $R_f = 0.18$ (silica gel, 80% EtOAc in hexanes); mp = 82-83 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ
41 (ppm) 8.15 – 8.01 (m, 1 H), 7.48 – 7.21 (m, 12 H), 7.12 – 6.99 (m, 1 H), 6.74 – 6.62 (m, 1 H),
42 5.84 – 5.67 (m, 1 H), 5.13 – 4.99 (m, 5 H), 4.83 – 4.64 (m, 4 H), 4.58 – 4.45 (m, 1 H), 3.76 (bs,
43 1 H), 2.71 (dt, $J = 14.8, 8.0$ Hz, 1 H), 2.50 (dt, $J = 13.6, 6.6$ Hz, 1 H), 1.53 – 1.25 (m, 3 H); ^{13}C
44 NMR (100 MHz, CDCl_3) δ (ppm) 172.3, 171.9, 159.1, 159.0, 137.6, 137.5, 137.5, 137.5, 137.4,
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 137.3, 137.3, 137.3, 136.9, 136.9, 134.5, 134.4, 128.5, 128.5, 128.5, 128.5, 128.1, 128.0, 127.9,
3
4 127.9, 127.6, 121.4, 121.2, 117.8, 117.7, 110.8, 110.6, 108.5, 108.2, 92.3, 92.3, 70.1, 70.0, 69.9,
5
6 61.4, 61.2, 51.4, 51.3, 40.1, 39.9, 16.4, 15.8. To a solution of the amine obtained above (105
7
8 mg, 0.23 mmol, 1.0 equiv) and Fmoc-Gly-OH (**35**) (88 mg, 0.30 mmol, 1.3 equiv) in CH₂Cl₂
9
10 (5 mL) was added HATU (130 mg, 0.34 mmol, 1.5 equiv) and DIPEA (0.1 mL, 0.46 mmol, 2.0
11
12 equiv) at 0 °C and the mixture was stirred for 15 h at 25 °C. After this time, a saturated aqueous
13
14 NH₄Cl solution was added and the organic layer was separated. The aqueous phase was
15
16 extracted with EtOAc, and the combined organic layers were washed with brine, dried over
17
18 anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The crude
19
20 product was purified by flash column chromatography (silica gel, 15% EtOAc in hexanes →
21
22 40% EtOAc in hexanes) to obtain peptide **81** (123 mg, 73%, 1:1 mixture of diastereoisomers)
23
24 as a white foam. Data assigned for the mixture of diastereoisomers: *R_f* = 0.27 (silica gel, 50%
25
26 EtOAc in hexanes); ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.99 – 7.96 (m, 1 H), 7.75 (dd, *J* =
27
28 7.5, 3.4 Hz, 2 H), 7.59 (d, *J* = 7.3 Hz, 2 H), 7.45 – 7.23 (m, 16 H), 7.03 (t, *J* = 8.9 Hz, 1 H),
29
30 6.71 – 6.66 (m, 1 H), 5.72 (ttd, *J* = 13.7, 7.0, 3.3 Hz, 1 H), 5.53 (bs, 1 H), 5.13 – 5.06 (m, 2 H),
31
32 5.04 (s, 2 H), 4.77 – 4.55 (m, 6 H), 4.44 (d, *J* = 6.8 Hz, 2 H), 4.22 (t, *J* = 6.9 Hz, 1 H), 3.97 –
33
34 3.78 (m, 2 H), 2.64 (dt, *J* = 16.3, 7.0 Hz, 1 H), 2.44 (ddd, *J* = 20.6, 13.8, 6.5 Hz, 1 H), 1.49 –
35
36 1.44 (m, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 174.6, 170.1, 170.0, 165.6, 159.1, 159.1,
37
38 156.8, 156.7, 143.7, 143.7, 141.3, 141.3, 137.2, 136.8, 134.2, 134.2, 130.0, 129.9, 128.6, 128.1,
39
40 128.1, 128.0, 127.8, 127.7, 127.6, 127.1, 127.0, 125.1, 125.0, 121.3, 121.2, 120.0, 119.9, 117.9,
41
42 117.9, 111.2, 111.2, 108.5, 108.3, 92.6, 92.5, 78.3, 77.8, 70.3, 70.2, 70.1, 65.4, 49.9, 47.1, 44.5,
43
44 38.7, 18.4, 18.3; HRMS (H-ESI) *m/z*: [M + H]⁺ calcd for C₄₅H₄₆N₃O₇ 740.3336; found
45
46 740.3327.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Diolefin 83. To a solution of peptide **81** (63 mg, 0.09 mmol, 1.0 equiv) in CH₂Cl₂ (5 mL) was added piperidine (0.04 mL, 0.43 mmol, 5.0 equiv) and the reaction mixture was stirred at 25 °C 5 h. After this time, the organic solvent was removed under reduced pressure and the resulting crude amine was used in the next step without purification. To a solution of the crude amine (~0.09 mmol) and acid **82** (10 μL, 0.11 mmol, 1.3 equiv) in CH₂Cl₂ (5 mL) was added HATU (49 mg, 0.13 mmol, 1.5 equiv) and DIPEA (30 μL, 0.17 mmol, 2.0 equiv) at 0 °C and the mixture was stirred for 12 h at 25 °C. After this time, a saturated aqueous NH₄Cl solution was added and the organic layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous MgSO₄, filtered and the solvent evaporated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 30% EtOAc in hexanes → 100% EtOAc) to obtain diolefin **83** (32 mg, 64% over 2 steps, 1:1 mixture of diastereoisomers) as a white solid. Data assigned for the mixture of diastereoisomers: R_f = 0.62 (silica gel, 100% EtOAc); mp = 95-96 °C; ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.95 (t, J = 2.6 Hz, 1 H), 7.46 – 7.27 (m, 12 H), 7.03 (t, J = 8.6 Hz, 1 H), 6.85 (s, 1 H), 6.69 (dt, J = 8.4, 2.8 Hz, 1 H), 5.99 – 5.84 (m, 1 H), 5.80 – 5.65 (m, 1 H), 5.27 – 5.19 (m, 2 H), 5.16 – 5.06 (m, 2 H), 5.05 (s, 2 H), 4.76 – 4.63 (m, 4 H), 4.56 – 4.46 (m, 2 H), 4.03 – 3.95 (m, 2 H), 3.07 – 3.00 (m, 2 H), 2.65 (ddd, J = 15.3, 13.9, 7.7 Hz, 1 H), 2.44 (ddd, J = 20.9, 13.1, 6.4 Hz, 1 H), 1.49 – 1.43 (m, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ (ppm) 174.5, 171.8, 171.4, 170.1, 168.8, 165.7, 160.2, 159.1, 140.9, 137.2, 137.1, 136.8, 136.8, 134.3, 134.2, 130.7, 129.9, 129.9, 128.8, 128.6, 128.1, 128.1, 128.0, 127.7, 127.7, 127.6, 127.0, 120.2, 120.1, 117.9, 117.8, 111.2, 111.1, 108.6, 108.4, 92.7, 92.5, 78.8, 70.3, 70.3, 70.2, 70.1, 50.1, 50.1, 43.1, 43.0, 41.2, 41.2, 38.7, 18.3, 18.2; HRMS (H-ESI) m/z : [M + H]⁺ calcd for C₃₄H₄₀N₃O₆ 586.2917; found 586.2905.

Macrocycle 85. To a stirred solution of macrocycle **27** (28 mg, 0.07 mmol, 1.0 equiv) in THF (10 mL) at $-78\text{ }^{\circ}\text{C}$ was added condensed liquid NH_3 ($\sim 8\text{ mL}$) *via* cannula. Then, small pieces of Na (130 mg, 5.61 mmol, 85 equiv) were added to the mixture until the formation of a deep blue solution. The reaction was stirred at $-78\text{ }^{\circ}\text{C}$ for 2 h and after this time it was quenched by slowly addition of MeOH at the same temperature. The mixture was allowed to reach room temperature and concentrated under reduced pressure to a volume of $\sim 10\text{ mL}$. The reaction was neutralized with Dowex- H^+ , washed with MeOH and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 7% MeOH in CH_2Cl_2) to obtain macrocycle **85** (18 mg, 85%) as a white solid: $R_f = 0.34$ (silica gel, 10% MeOH in CH_2Cl_2); $[\alpha]_{\text{D}}^{25} = -6.77$ ($c\ 0.09$, MeOH); $\text{mp} = 125\text{-}126\text{ }^{\circ}\text{C}$; $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ (ppm) 9.30 (bs, 1 H), 8.51 (d, $J = 7.2\text{ Hz}$, 1 H), 8.38 (bs, 1 H), 7.03 (d, $J = 2.4\text{ Hz}$, 1 H), 6.91 (d, $J = 8.2\text{ Hz}$, 1 H), 6.49 (dd, $J = 8.2, 2.5\text{ Hz}$, 1 H), 5.40 (dt, $J = 15.1, 5.0\text{ Hz}$, 1 H), 5.07 (dt, $J = 15.1, 5.7\text{ Hz}$, 1 H), 4.32 (p, $J = 7.0\text{ Hz}$, 1 H), 4.11 (bs, 1 H), 3.84 (dd, $J = 14.8, 6.4\text{ Hz}$, 1 H), 3.43 (dd, $J = 14.8, 5.6\text{ Hz}$, 1 H), 3.16 – 3.09 (m, 1 H), 2.96 (dd, $J = 16.4, 5.2\text{ Hz}$, 1 H), 2.28 – 2.08 (m, 4 H), 1.29 (d, $J = 7.1\text{ Hz}$, 3 H); $^{13}\text{C NMR}$ (100 MHz, $\text{DMSO-}d_6$) δ 173.1, 171.2, 170.9, 156.3, 136.9, 131.4, 131.0, 127.8, 123.7, 112.7, 112.4, 49.7, 49.1, 43.4, 33.8, 27.9, 16.9; HRMS (H-ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{22}\text{N}_3\text{O}_4$ 332.1610; found 332.1618.

Cell growth assay. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or MTT dye reduction assay in 96-well microplates was used.³² This assay is dependent on the reduction of MTT by mitochondrial dehydrogenases of a viable cell to a blue formazan product, which can be measured spectrophotometrically. 2.5×10^3 BAEC, 3×10^3 HL-60 and KU812F and 2×10^3 HepG2, HT-1080, HT-29, MDA-MB-231, U2OS, U937 and U87MG cells in a total volume of 100 μL of their respective growth medium were incubated with serial dilutions 1:1 of the tested compounds. After 3 days of incubation ($37\text{ }^{\circ}\text{C}$ and 5% CO_2 in a humid

1
2 atmosphere), 10 μ L of MTT (5 mg/mL in phosphate-buffered saline) were added to each well,
3
4 and the plate was incubated for a further 4 h at 37 °C. The resulting formazan was dissolved in
5
6 150 μ L of 0.04 N HCl/2-propanol and read at 550 nm. IC₅₀ values were calculated from semi-
7
8 logarithmic dose-response plots as those concentrations of compound yielding 50% cell
9
10 survival, taking the values obtained for the control to be 100%. IC₅₀ results are expressed as
11
12 means \pm S.D. of at least three independent experiments.
13
14

15 16 ASSOCIATED CONTENT

17 18 19 Supporting Information

20
21 The Supporting Information is available free of charge on the ACS Publications website at DOI:
22
23 ¹H and ¹³C NMR spectra for all new compounds, dose-response plots of the biological studies
24
25 and theoretical calculations data.
26
27
28

29 30 AUTHOR INFORMATION

31 32 Corresponding Author

33
34 * E-mail: frsarabia@uma.es
35
36
37

38 39 Author Contributions

40
41 The manuscript was written through contributions of all authors. / All authors have given
42
43 approval to the final version of the manuscript. / ‡I. C.-S. performed all the synthetic work and
44
45 designed the experiments. A. S.-R. and J. M. L.-R. performed the theoretical calculations. P. C.,
46
47 B. M.-P., A. R. Q. and M. A. M. performed the biological evaluations. F. S. and I. C.-S.
48
49 conceived and directed the study.
50

51 52 Notes

53
54 The authors declare no competing financial interest.
55
56

57 58 ACKNOWLEDGMENT

This work was financially supported by the Ministerio de Ciencias e Innovación (MICINN) (ref. CTQ2014-60223-R and CTQ2016-76311-R) and Junta de Andalucía and “Fondo Europeo de Desarrollo Regional-FEDER” (P12 CTS-1507). I. C.-S. thanks Ministerio de Educación, Cultura y Deporte for a predoctoral fellowship (FPU programme). The authors thank Dr. J. I. Trujillo from Pfizer (Groton, CT) for assistance in the preparation of this manuscript. The authors thank the Unidad de Espectroscopía de Masas and the NMR facility of the University of Málaga for exact mass and NMR spectroscopic assistance.

REFERENCES

1. Festa, C.; De Marino, S.; Sepe, V.; D’Auria, M. V.; Bifulco, G.; Débitus, C.; Bucci, M.; Vellecco, V.; Zampella, A. *Org. Lett.* **2011**, *13*, 1532–1535.
2. (a) Wegerski, C. J.; Hammond, J.; Tenney, K.; Matainaho, T.; Crews, P. *J. Nat. Prod.* **2007**, *70*, 89–94. (b) Festa, C.; De Marino, S.; Sepe, V.; Monti, M. C.; Luciano, P.; D’Auria, M. V.; Débitus, C.; Bucci, M.; Vellecco, V.; Zampella, A. *Tetrahedron* **2009**, *65*, 10424–10429 and references therein.
3. (a) Kavitha, N.; Kumar, V. P.; Chandrasekhar, S. *Tetrahedron Lett.* **2013**, *54*, 2128–2130. (b) Kavitha, N.; Chandrasekhar, S. *Org. Biomol. Chem.* **2015**, *13*, 6242–6248.
4. (a) Kashinath, K.; Vasudevan, N.; Reddy, D. S. *Org. Lett.* **2012**, *14*, 6222–6225. (b) Kashinath, K.; Dhara, S.; Reddy, D. S. *Org. Lett.* **2015**, *17*, 2090–2093.
5. Vasudevan, N.; Kashinath, K.; Reddy, D. S. *Org. Lett.* **2014**, *16*, 6148–6151.
6. Reddy, D. S.; Kormirishetty, K.; Natrajan, V. WO Patent 2014083578 A1, Nov 27, 2013; *Chem. Abstr.* **2014**, *161*, 70679.
7. Kashinath, K.; Jachak, G. R.; Athawale, P. R.; Marelli, U. K.; Gonnade, R. G.; Reddy, D. S. *Org. Lett.* **2016**, *18*, 3178–3181.

- 1
2 8. (a) Sarabia, F.; Chammaa, S.; Sánchez-Ruiz, A.; Martín-Ortiz, L.; López-Herrera, F. J. *Curr.*
3
4 *Med. Chem.* **2004**, *11*, 1309–1332. (b) Sarabia, F.; Chammaa, S. *J. Org. Chem.* **2005**, *70*,
5
6 7846–7857. (c) Sarabia, F.; Chammaa, S.; García-Castro, M. *J. Org. Chem.* **2005**, *70*,
7
8 7858–7865. (d) Sarabia, F.; Chammaa, S.; García-Ruiz, C. *J. Org. Chem.* **2011**, *76*,
9
10 2132–2144. (e) Goh, S.; Hohmeier, A.; Stone, T. C.; Offord, V.; Sarabia, F.; García-Ruiz,
11
12 C.; Good, L. *Appl. Environ. Microbiol.* **2015**, *81*, 5650–5659.
13
14
15
16 9. Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. *Angew. Chem. Int. Ed.* **2005**, *44*, 4490–4527.
17
18
19 10. Cheng-Sánchez, I.; García-Ruiz, C.; Sarabia, F. *Tetrahedron Lett.* **2016**, *57*, 3392–3395.
20
21
22 11. Jin-Gim, H.; Li, H.; Lee, E.; Ryu, J.-H.; Jeon, R. *Bioorg. Med. Chem. Lett.* **2013**, *23*,
23
24 513–517.
25
26 12. Asif, K.; Himaja, M.; Ramana, M. V.; Sikarwar, M. S. *Asian J. Chem.* **2012**, *24*, 2739–2743.
27
28
29 13. Hong, S. H.; Sanders, D. P.; Lee, C. W.; Grubbs, R. H. *J. Am. Chem. Soc.* **2005**, *127*,
30
31 17160–17161.
32
33
34 14. For representative examples of the influence of the structural pattern in the stereochemistry
35
36 of the ring-closing metathesis, see: (a) Nicolaou, K. C.; He, Y.; Vourloumis, D.; Vallberg,
37
38 H.; Roschangar, F.; Sarabia, F.; Ninkovic, S.; Yang, Z.; Trujillo, J. I. *J. Am. Chem. Soc.*
39
40 **1997**, *119*, 7960–7973. (b) Vassilikogiannakis, G.; Margaros, I.; Tofi, M. *Org. Lett.* **2004**,
41
42 *6*, 205–208. (c) Nicolaou, K. C.; Montagnon, T.; Vassilikogiannakis, G.; Mathison, C. J.
43
44 *N. J. Am. Chem. Soc.* **2005**, *127*, 8872–8888.
45
46
47 15. (a) Hoye, T. R.; Zhao, H. *Org. Lett.* **1999**, *1*, 1123–1125. (b) Maishal, T. K.; Sinha-
48
49 Mahapatra, D. K.; Paranjape, K.; Sarkar, A. *Tetrahedron Lett.* **2002**, *43*, 2263–2267. (c)
50
51 Imahori, T.; Ojima, H.; Tateyama, H.; Mihara, Y.; Takahata, H. *Tetrahedron Lett.* **2008**,
52
53 *49*, 265–268. (d) Imahori, T.; Ojima, H.; Yoshimura, Y.; Takahata, H. *Chem. Eur. J.* **2008**,
54
55 *14*, 10762–10771.
56
57
58
59
60

- 1
2 16. (a) Cheng-Sánchez, I.; García-Ruiz, C.; Guerrero-Vásquez, G. A.; Sarabia, F. *J. Org.*
3
4 *Chem.* **2017**, *82*, 4744–4757. (b) Paquette, L. A.; Efremov, I. *J. Am. Chem. Soc.* **2001**, *123*,
5
6 4492–4501. (c) Gurjar, M. K.; Yakambram, P. *Tetrahedron Lett.* **2001**, *42*, 3633–3636.
7
8
9 17. Carrión, M. D.; Chayah, M.; Entrena, A.; López, A.; Gallo, M. A.; Acuña-Castroviejo, D.;
10
11 Camacho, M. E. *Bioorg. Med. Chem.* **2013**, *21*, 4132–4142.
12
13
14 18. For a comprehensive revision of different methods of Boc cleavage see: (a) Dandepally, S.
15
16 R.; Williams, A. L. *Tetrahedron Lett.* **2009**, *50*, 1071–1074. (b) Kumar, G. P.; Rambabu,
17
18 D.; Rao, M. V. B.; Pal, M. *J. Chem.* **2013**, *2013*, 916960; *Chem. Abstr.* **2013**, *160*, 723475.
19
20
21 19. Hengartner, U.; Batcho, A. D.; Blount, J. F.; Leimgruber, W.; Larscheid, M. E.; Scott, J.
22
23 *W. J. Org. Chem.* **1979**, *44*, 3748–3752.
24
25
26 20. (a) Martín-Ortiz, L.; Chammaa, S.; Pino-González, M. S.; Sánchez-Ruiz, A.; García-Castro,
27
28 M.; Assiego, C.; Sarabia, F. *Tetrahedron Lett.* **2004**, *45*, 9069–9072. (b) Miyashita, M.;
29
30 Mizutani, T.; Tadano, G.; Iwata, Y.; Miyazawa, M.; Tanino, K. *Angew. Chem. Int. Ed.*
31
32 **2005**, *44*, 5094–5097. (c) Yu, X.-Q.; Yoshimura, F.; Ito, F.; Sasaki, M.; Hirai, A.; Tanino,
33
34 K.; Miyashita, M. *Angew. Chem. Int. Ed.* **2008**, *47*, 750–754.
35
36
37 21. Yang, D.; Wong, M.-K.; Yip, Y.-C. *J. Org. Chem.* **1995**, *60*, 3887–3889.
38
39
40 22. DFT calculations were carried out using Gaussian 09 at the B3LYP/6-31G' level of theory
41
42 using the SMD solvation methodology, choosing acetonitrile as solvent.
43
44
45 23. Aoyama, A.; Endo-Umeda, K.; Kishida, K.; Ohgane, K.; Noguchi-Yachide, T.; Aoyama,
46
47 H.; Ishikawa, M.; Miyachi, H.; Makishima, M.; Hashimoto, Y. *J. Med. Chem.* **2012**, *55*,
48
49 7360–7377.
50
51
52 24. Wagner, H.; Harms, K.; Koert, U.; Meder, S.; Boheim, G. *Angew. Chem. Int. Ed.* **1996**, *35*,
53
54 2643–2646.
55
56
57 25. Engelhardt, F. C.; Schmitt, M. J.; Taylor, R. E. *Org. Lett.* **2001**, *3*, 2209–2212.
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
26. Hoveyda, A. H.; Lombardi, P. J.; O'Brien, R. V.; Zhugralin, A. R. *J. Am. Chem. Soc.* **2009**, *131*, 8378–8379.
27. (a) Lin, Y. A.; Davis, B. G. *Beilstein J. Org. Chem.* **2010**, *6*, 1219–1228. (b) Fuwa, H.; Saito, A.; Sasaki, M. *Angew. Chem. Int. Ed.* **2010**, *49*, 3041–3044. (c) Schmidt, B.; Staude, L. *J. Org. Chem.* **2009**, *74*, 9237–9240. (d) Schmidt, B.; Nave, S. *Chem. Commun.* **2006**, 2489–2491.
28. (a) Fürstner, A.; Thiel, O. R.; Lehmann, C. W. *Organometallics* **2002**, *21*, 331–335. (b) Choi, T.-L.; Chatterjee, A. K.; Grubbs, R. H. *Angew. Chem. Int. Ed.* **2001**, *40*, 1277–1279. (c) Chatterjee, A. K.; Choi, T.-L.; Sanders, D. P.; Grubbs, R. H. *J. Am. Chem. Soc.* **2003**, *125*, 11360–11370.
29. For representative examples see: (a) Lübke, C.; Dumrath, A.; Neumann, H.; Beller, M.; Kadyrov, R. *ChemCatChem* **2014**, *6*, 105–108. (b) Nagarapu, L.; Gaikwad, H. K.; Bantu, R.; Manikonda, S. R.; Kumar, C. G.; Pombala, S. *Tetrahedron Lett.* **2012**, *53*, 1287–1291. (c) Pentzer, E. B.; Gadzikwa, T.; Nguyen, S. T. *Org. Lett.* **2008**, *10*, 5613–5615. (d) Vedrenne, E.; Dupont, H.; Oualef, S.; Elkaïm, L.; Grimaud, L. *Synlett* **2005**, 670–672.
30. Cárdenas, C; Quesada, A. R.; Medina, M. A. *Cell. Mol. Life Sci.* **2006**, *63*, 3083–3089.
31. Minimum energy conformations were calculated using the PM3 method found in HyperChem 5.0 software. Optimization was performed using Polak-Ribiere algorithm until the RMS gradient reached a value below 0.001 kcal/(Å·mol).
32. Mosmann, T. *J. Immunol. Methods* **1983**, *65*, 55–63.